U.S. patent application number 13/826258 was filed with the patent office on 2013-10-10 for chimeric receptors with 4-1bb stimulatory signaling domain.
The applicant listed for this patent is St. Jude Children's Research Hospital, Inc.. Invention is credited to DARIO CAMPANA, CHIHAYA IMAI.
Application Number | 20130266551 13/826258 |
Document ID | / |
Family ID | 49292463 |
Filed Date | 2013-10-10 |
United States Patent
Application |
20130266551 |
Kind Code |
A1 |
CAMPANA; DARIO ; et
al. |
October 10, 2013 |
CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN
Abstract
The present invention relates to a chimeric receptor capable of
signaling both a primary and a co-stimulatory pathway, thus
allowing activation of the co-stimulatory pathway without binding
to the natural ligand. The cytoplasmic domain of the receptor
contains a portion of the 4-1BB signaling domain. Embodiments of
the invention relate to polynucleotides that encode the receptor,
vectors and host cells encoding a chimeric receptor, particularly
including T cells and natural killer (NK) cells and methods of
use.
Inventors: |
CAMPANA; DARIO; (SINGAPORE,
SG) ; IMAI; CHIHAYA; (NIIGATA CITY, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
St. Jude Children's Research Hospital, Inc. |
Memphis |
TN |
US |
|
|
Family ID: |
49292463 |
Appl. No.: |
13/826258 |
Filed: |
March 14, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13761917 |
Feb 7, 2013 |
|
|
|
13826258 |
|
|
|
|
13548148 |
Jul 12, 2012 |
8399645 |
|
|
13761917 |
|
|
|
|
13244981 |
Sep 26, 2011 |
|
|
|
13548148 |
|
|
|
|
12206204 |
Sep 8, 2008 |
8026097 |
|
|
13244981 |
|
|
|
|
11074525 |
Mar 8, 2005 |
7435596 |
|
|
12206204 |
|
|
|
|
10981352 |
Nov 4, 2004 |
|
|
|
11074525 |
|
|
|
|
60517507 |
Nov 5, 2003 |
|
|
|
Current U.S.
Class: |
424/93.21 ;
435/320.1; 435/328; 530/387.3; 536/23.4 |
Current CPC
Class: |
C07K 16/2866 20130101;
C07K 2317/569 20130101; C12N 2501/2302 20130101; C07K 2319/00
20130101; C07K 2319/30 20130101; C12N 5/0646 20130101; C07K 16/2878
20130101; C07K 2317/622 20130101; C07K 14/70578 20130101; C12N
2501/2315 20130101; C07K 14/7051 20130101; C07K 16/2803 20130101;
C12N 2502/99 20130101; C07K 16/2896 20130101; C07K 2319/03
20130101; A61K 39/0011 20130101; C12N 2501/599 20130101; C07K
2319/02 20130101; C12N 2510/00 20130101; C07K 14/70517
20130101 |
Class at
Publication: |
424/93.21 ;
530/387.3; 536/23.4; 435/320.1; 435/328 |
International
Class: |
C07K 16/28 20060101
C07K016/28 |
Goverment Interests
1. GOVERNMENT INTEREST
[0002] This invention was made in part with U.S. Government support
under National Institutes of Health grant No. CA 58297. The U.S.
Government may have certain rights in this invention.
Claims
1. A chimeric antigen receptor comprising: (a) an extracellular
ligand-binding domain comprising an anti-CD 19 single chain
variable fragment (scFv) domain; (b) a transmembrane domain; and
(c) a cytoplasmic domain comprising a 4-1BB signaling domain and a
CD3.zeta. signaling domain wherein the CD3.zeta. signaling domain
comprises the amino acid sequence of SEQ ID No. 18.
2. The chimeric antigen receptor of claim 1, wherein the
extracellular binding domain comprises the amino acid sequence of
SEQ. ID. No. 10.
3. The chimeric antigen receptor of claim 1 wherein the
transmembrane domain comprises the amino acid sequence of SEQ ID
No. 14.
4. The chimeric antigen receptor of claim 1 wherein the 4-1BB
signaling domain comprises the amino acid sequence of SEQ ID No.
16.
5. The chimeric antigen receptor of claim 1 comprising the amino
acid sequence of SEQ. ID. No. 6.
6. A polynucleotide encoding the CAR of claim 1.
7. The polynucleotide of claim 6, wherein the a cytoplasmic domain
is encoded by the nucleic acid sequence of SEQ ID No. 15.
8. The polynucleotide claim 6, wherein the extracellular binding
domain is encoded by the nucleic acid sequence of SEQ. ID. No.
9.
9. The polynucleotide of claim 6, wherein the transmembrane domain
is encoded by the nucleic acid sequence of SEQ ID No. 13.
10. The polynucleotide of claim 6, wherein the CD3.zeta. signaling
domain is encoded by the nucleic acid sequence of either SEQ ID No.
17.
11. The polynucleotide of claim 6 comprising the nucleotide
sequence of SEQ. ID. No. 5.
12. A vector comprising the polynucleotide of claim 11.
13. The vector of claim 12 which is a retroviral vector.
14. An isolated host cell comprising the polynucleotide of claim
11.
15. The isolated host cell of claim 14 which is a T lymphocyte.
16. The isolated host cell of claim 14 which is an autologous
cell.
17. The isolated host cell of claim 14 which is isolated from a
patient having a cancer of B cell origin.
18. The isolated host cell of claim 16, wherein the autologous cell
is an autologous T lymphocyte.
19. The isolated host cell of claim 18, wherein the autologous T
lymphocyte is derived from a blood or tumor sample of a patient
having a cancer of B cell origin and activated and expanded in
vitro.
20. The isolated host cell of claim 17 which is isolated from a
patient having lymphoblastic leukemia, B-lineage acute
lymphoblastic leukemia, B-cell chronic lymphocytic leukemia or
B-cell non-Hodgkin's lymphoma.
21. The isolated host cell of claim 17, which is isolated from a
patient having lung cancer, melanoma, breast cancer, prostate
cancer, colon cancer, renal cell carcinoma, ovarian cancer,
neuroblastoma, rhabdomyosarcoma, leukemia and lymphoma, acute
lymphoblastic leukemia, small cell lung cancer, Hodgkin's lymphoma,
or childhood acute lymphoblastic leukemia.
22. The isolated host cell of claim 18, wherein the autologous T
lymphocyte is derived from a blood or tumor sample of a patient
having a cancer of B cell origin and activated and expanded in
vitro.
23. A method of enhancing a T lymphocyte or an NK cell activity in
a mammal comprising introducing into the mammal a T lymphocyte or
NK cell, which T lymphocyte or NK cell comprises a chimeric
receptor comprising: (a) an extracellular ligand-binding domain
comprising an anti-CD19 single chain variable fragment (scFv)
domain, (b) a hinge and transmembrane domain, and (c) a cytoplasmic
domain comprising a 4-1BB signaling domain and a CD3.zeta.
signaling domain comprising the amino acid sequence of SEQ ID No.
18.
24. A method for treating a mammal suffering from cancer comprising
introducing into the mammal a T lymphocyte or an NK cell, which T
lymphocyte or NK cell comprises a chimeric receptor comprising: (a)
an extracellular ligand-binding domain comprising an anti-CD19 scFv
domain; (b) a hinge region and transmembrane domain of CD8.alpha.;
and (c) a cytoplasmic domain comprising a signaling domain of 4-1BB
and a CD3.zeta. signaling domain comprising the amino acid sequence
of SEQ ID No. 18.
25. A method for stimulating a T cell-mediated immune response to a
target cell population or tissue in a mammal comprising
administering to a mammal an effective amount of a cell genetically
modified to express a chimeric antigen receptor (CAR), said CAR
comprising: a) an extracellular ligand-binding domain comprising an
anti-CD19 single chain variable fragment (scFv) domain, (b) a hinge
and transmembrane domain, and (c) a cytoplasmic domain comprising a
4-1BB signaling domain and a CD3 signaling domain comprising the
amino acid sequence of SEQ ID No. 18.
26. A method of providing an anti-tumor immunity in a mammal, the
method comprising administering to the mammal an effective amount
of a cell genetically modified to express a CAR, said CAR
comprising: a) an extracellular ligand-binding domain comprising an
anti-CD19 single chain variable fragment (scFv) domain, (b) a hinge
and transmembrane domain, and (c) a cytoplasmic domain comprising a
4-1BB signaling domain and a CD3 signaling domain comprising the
amino acid sequence of SEQ ID No. 18.
27. A method of treating a mammal having a disease, disorder or
condition associated with an elevated expression of a tumor
antigen, the method comprising administering to the mammal an
effective amount of a cell genetically modified to express a CAR,
said CAR comprising comprising an antigen binding domain, a
costimulatory signaling region, and a CD3 zeta signaling domain
comprising the amino acid sequence of SEQ ID No. 18, thereby
treating the mammal.
28. A method of treating a human with chronic lymphocytic leukemia,
the method comprising administering to the human a T cell
genetically engineered to express a CAR wherein the CAR comprises
an antigen binding domain, a costimulatory signaling region, and a
CD3 zeta signaling domain comprising the amino acid sequence of SEQ
ID No. 18.
29. A method of generating a persisting population of genetically
engineered T cells in a human diagnosed with cancer, said method
comprising administering to the human a T cell genetically
engineered to express a CAR, said CAR comprising: a) an
extracellular ligand-binding domain comprising an anti-CD19 single
chain variable fragment (scFv) domain, (b) a hinge and
transmembrane domain an antigen binding domain, and (c) a
cytoplasmic domain comprising a signaling region comprising a
costimulatory domain and a CD3 zeta signaling domain comprising the
amino acid sequence of SEQ ID No. 18.
30. A method of expanding a population of genetically engineered T
cells in a human diagnosed with cancer, the method comprising
administering to the human aT cell genetically engineered to
express a CAR, said CAR comprising: an antigen binding domain, a
costimulatory signaling region, and a CD3 zeta signaling domain
comprising the amino acid sequence of SEQ ID NO: 18, wherein the
administered genetically engineered T cell produces a population of
progeny T cells in the human.
31. The method of any one of claims 24 to 28, wherein the mammal is
suffering from B-lineage acute lymphoblastic leukemia, B-cell
chronic lymphocytic leukemia, B-cell non-Hodgkin's lymphoma lung
cancer, melanoma, breast cancer, prostate cancer, colon cancer,
renal cell carcinoma, ovarian cancer, neuroblastoma,
rhabdomyosarcoma, leukemia and lymphoma, acute lymphoblastic
leukemia, small cell lung cancer, Hodgkin's lymphoma, or childhood
acute lymphoblastic leukemia.
Description
2. CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S.
application Ser. No. 13/761,917, filed on Feb. 7, 2013, which is a
divisional application of U.S. patent application Ser. No.
13/548,148, filed on Jul. 12, 2012, which is a continuation of U.S.
application Ser. No. 13/244,981, filed on Sep. 26, 2011, which is a
continuation of U.S. patent application Ser. No. 12/206,204, filed
on Sep. 8, 2008 (granted as U.S. Pat. No. 8,026,097), which is a
continuation of U.S. patent application Ser. No. 11/074,525, filed
on Mar. 8, 2005 (granted as U.S. Pat. No. 7,435,596), which is a
continuation-in-part of U.S. patent application Ser. No.
10/981,352, filed on Nov. 4, 2004 (abandoned), which claims the
benefit of U.S. Provisional Patent Application Ser. No. 60/517,507,
filed on Nov. 5, 2003, each of which is incorporated herein by
reference in its entirety.
[0003] The instant application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web and is hereby
incorporated by reference in its entirety. The Sequence Listing is
being concurrently submitted via EFS-Web as an ASCII text file
named 13213-008-999_Sequence.sub.--Listing.TXT, created Mar. 14,
2013, and being 36,943 bytes in size.
3. FIELD OF THE INVENTION
[0004] This invention relates to chimeric cell membrane receptors,
particularly chimeric T-cell receptors. This invention further
relates to activation and expansion of cells for therapeutic uses,
in particular for activation and expansion of NK cells for chimeric
receptor-based cell therapy.
4. BACKGROUND
[0005] Regulation of cell activities is frequently achieved by the
binding of a ligand to a surface membrane receptor comprising an
extracellular and a cytoplasmic domain. The formation of the
complex between the ligand and the extracellular portion of the
receptor results in a conformational change in the cytoplasmic
portion of the receptor which results in a signal transduced within
the cell. In some instances, the change in the cytoplasmic portion
results in binding to other proteins, where other proteins are
activated and may carry out various functions. In some situations,
the cytoplasmic portion is autophosphorylated or phosphorylated,
resulting in a change in its activity. These events are frequently
coupled with secondary messengers, such as calcium, cyclic
adenosine monophosphate, inositol phosphate, diacylglycerol, and
the like. The binding of the ligand to the surface membrane
receptor results in a particular signal being transduced.
[0006] For T-cells, engagement of the T-cell receptor (TCR) alone
is not sufficient to induce persistent activation of resting naive
or memory T cells. Full, productive T cell activation requires a
second co-stimulatory signal from a competent antigen-presenting
cell (APC). Co-stimulation is achieved naturally by the interaction
of the co-stimulatory cell surface receptor on the T cell with the
appropriate counter-receptor on the surface of the APC. An APC is
normally a cell of host origin which displays a moiety which will
cause the stimulation of an immune response. APCs include
monocyte/macrophages, dendritic cells, B cells, and any number of
virally-infected or tumor cells which express a protein on their
surface recognized by T cells. To be immunogenic APCs must also
express on their surface a co-stimulatory molecule. Such APCs are
capable of stimulating T cell proliferation, inducing cytokine
production, and acting as targets for cytolytic T cells upon direct
interaction with the T cell. See Linsley and Ledbetter, Ann. Rev.
Immunol. 4:191-212 (1993); Johnson and Jenkins, Life Sciences
55:1767-1780 (1994); June et al., Immunol. Today 15:321-331 (1994);
and Mondino and Jenkins, J. Leuk. Biol. 55:805-815 (1994).
[0007] Engagement of the co-stimulatory molecule together with the
TCR is necessary for optimal levels of IL-2 production,
proliferation and clonal expansion, and generation of effector
functions such as the production of immunoregulatory cytokines,
induction of antibody responses from B cells, and induction of
cytolytic activity. More importantly, engagement of the TCR in the
absence of the co-stimulatory signal results in a state of
non-responsiveness, called anergy. Anergic cells fail to become
activated upon subsequent stimulation through the TCR, even in the
presence of co-stimulation, and in some cases may be induced to die
by a programmed self-destruct mechanism.
[0008] In certain situations, for example where APCs lack the
counter-receptor molecules necessary for co-stimulation, it would
be beneficial to have the co-stimulatory signal induced by virtue
of employing a ligand other than the natural ligand for the
co-stimulatory receptor. This might be, for example, the same
ligand as that recognized by the TCR (i.e., the same moiety, such
that if one signal is received, both signals will be received), or
another cell surface molecule known to be present on the target
cells (APCs).
[0009] Several receptors that have been reported to provide
co-stimulation for T-cell activation, including CD28, OX40, CD27,
CD2, CD5, ICAM-1, LFA-1 (CD11a/CD18), and 4-1BB. The signaling
pathways utilized by these co-stimulatory molecules share the
common property of acting in synergy with the primary T cell
receptor activation signal.
[0010] Previously the signaling domain of CD28 has been combined
with the T-cell receptor to form a co-stimulatory chimeric
receptor. See U.S. Pat. No. 5,686,281; Geiger, T. L. et al., Blood
98: 2364-2371 (2001); Hombach, A. et al., J Immunol 167: 6123-6131
(2001); Maher, J. et al. Nat Biotechnol 20: 70-75 (2002); Haynes,
N. M. et al., J Immunol 169: 5780-5786 (2002); Haynes, N. M. et
al., Blood 100: 3155-3163 (2002). These co-stimulatory receptors
provide a signal that is synergistic with the primary effector
activation signal, i.e. the TCR signal or the chimeric effector
function receptor signal, and can complete the requirements for
activation under conditions where stimulation of the TCR or
chimeric effector function receptor is suboptimal and might
otherwise be detrimental to the function of the cell. These
receptors can support immune responses, particularly of T cells, by
permitting the use of ligands other than the natural ligand to
provide the required co-stimulatory signal.
[0011] Chimeric receptors that contain a CD19 specific single chain
immunoglobulin extracellular domain have been shown to lyse CD19+
target cells and eradicate CD19+ B cell lymphomas engrafted in mice
[Cooper L J, et al., Blood 101:1637-1644 (2003) and Brentjens R J,
et al., Nature Medicine 9:279-286 (2003)]. Cooper et al. reported
that T-cell clones transduced with chimeric receptors comprising
anti-CD19 scFv and CD3.zeta. produced approximately 80% specific
lysis of B-cell leukemia and lymphoma cell lines at a 1:1 effector
to target ratio in a 4-hour Cr release assay; at this ratio,
percent specific lysis of one primary B-lineage ALL sample tested
was approximately 30%. Brentjens et al. reported that T-cells
bearing anti-CD19 scFv and CD3.zeta. chimeric receptors could be
greatly expanded in the presence of exogenous IL-15 and artificial
antigen-presenting cells transduced with CD19 and CD80. The authors
showed that these T cells significantly improved the survival of
immunodeficient mice engrafted with the Raji B-cell lymphoma cell
line. Their results also confirmed the importance of co-stimulation
in maximizing T-cell-mediated anti-leukemic activity. Only cells
expressing the B7 ligands of CD28 elicited effective T-cell
responses. This could be a major obstacle in the case of B-lineage
ALL because leukemic lymphoblasts typically do not express B7
molecules.
[0012] In addition to T cell immune responses, natural killer (NK)
cell responses appear to be clinically relevant. While T cells
recognize tumor associated peptide antigen expressed on surface HLA
class I or class II molecules, antigen nonspecific immune responses
are mediated by NK cells that are activated by the failure to
recognize cognate "self" HLA class 1 molecules. The
graft-versus-tumor effect of transplants using HLA matched donors
is mediated by antigen specific T cells, while transplantation
using HLA mismatched donors can also lead to donor NK cells with
potent antitumor activity. HLA mismatched haplo-identical
transplants can exert a powerful anti-leukemia effect based on
expansion of antigen nonspecific donor NK cells.
[0013] Immunotherapy with NK cells has been limited by the
inability to obtain sufficient numbers of pure NK cells suitable
for manipulation and expansion. The established methods for cell
expansion favor T cell expansion and even after T cells are
depleted, residual T cells typically become prominent after
stimulation. Thus there is a need for better methods to expand NK
cells from a population without expanding T cells.
5. SUMMARY OF THE INVENTION
[0014] The present invention provides a chimeric receptor
containing a co-stimulatory signal by incorporation of the
signaling domain of the 4-1BB receptor. The chimeric receptor
comprises an extracellular ligand binding domain, a transmembrane
domain and a cytoplasmic domain wherein the cytoplasmic domain
comprises the signaling domain of 4-1BB. In one embodiment of the
invention the signaling domain of 4-1BB used in the chimeric
receptor is of human origin. In a preferred embodiment, human 4-1BB
consists of SEQ ID NO:2. In another embodiment the signaling domain
comprises amino acids 214-255 of SEQ ID NO:2.
[0015] In another embodiment of the invention the cytoplasmic
domain of the chimeric receptor comprises the signaling domain of
CD3.zeta. in addition to the signaling domain of 4-1BB. In another
embodiment the extracellular domain comprises a single chain
variable domain of an anti-CD19 monoclonal antibody. In another
embodiment the transmembrane domain comprises the hinge and
transmembrane domains of CD8.alpha.. In a most preferred embodiment
of the invention the extracellular domain comprises a single chain
variable domain of an anti-CD19 monoclonal antibody, the
transmembrane domain comprises the hinge and transmembrane domain
of CD8.alpha., and the cytoplasmic domain comprises the signaling
domain of CD3.zeta. and the signaling domain of 4-1BB.
[0016] Other aspects of the invention include polynucleotide
sequences, vectors and host cells encoding a chimeric receptor that
comprises the signaling domain of 4-1BB. Yet other aspects include
methods of enhancing T lymphocyte or natural killer (NK) cell
activity in an individual and treating an individual suffering from
cancer by introducing into the individual a T lymphocyte or NK cell
comprising a chimeric receptor that comprises the signaling domain
of 4-1BB. These aspects particularly include the treatment of lung
cancer, melanoma, breast cancer, prostate cancer, colon cancer,
renal cell carcinoma, ovarian cancer, neuroblastoma,
rhabdomyosarcoma, leukemia and lymphoma. Preferred cancer targets
for use with the present invention are cancers of B cell origin,
particularly including acute lymphoblastic leukemia, B-cell chronic
lymphocytic leukemia and B-cell non-Hodgkin's lymphoma.
[0017] A different but related aspect of the present invention
provides a method for obtaining an enriched NK cell population
suitable for transduction with a chimeric receptor that comprises
the signaling domain of 4-1BB. This method comprises the expansion
of NK cells within a mixed population of NK cells and T cells by
co-culturing the mixed population of cells with a cell line that
activates NK cells and not T lymphocytes. This NK activating cell
line is composed of cells that activate NK cells, but not T
lymphocytes, and which express membrane bound interleukin-15 and a
co-stimulatory factor ligand. In a particular embodiment the NK
activating cell line is the K562 myeloid leukemia cell line or the
Wilms tumor cell line HFWT. In another embodiment of the invention
the co-stimulatory factor ligand is CD137L.
[0018] Another aspect of the present invention is based on the
concept that expression of chimeric receptors on NK cells could
overcome HLA-mediated inhibitory signals, thus endowing the cells
with cytotoxicity against otherwise NK-resistant cells. The
invention provides a method that allows specific and vigorous
preferential expansion of NK cells lacking T-cell receptors (CD56+
CD3-cells) and their highly efficient transduction with chimeric
receptors.
[0019] Provided herein are anti-CD 19-BB-.zeta. chimeric receptors
comprising an extracellular ligand-binding domain that comprises an
anti-CD 19 single chain variable fragment domain plus a signal
peptide of CD8.alpha., a hinge region and transmembrane domain of
CD8.alpha., and a cytoplasmic domain comprising the signaling
domain of 4-1BB and the signaling domain of CD3.zeta.. In one
aspect, the 4-1BB signaling domain is a human 4-1BB having the
amino acid sequence set forth in SEQ ID NO:2. Also provided is a
polynucleotide encoding the anti-CD19 chimeric receptor, a vector
for recombinant expression of the chimeric antigen receptor that
comprises the polynucleotide operatively linked to at least one
regulatory element in the appropriate orientation for expression,
and a host cell expressing the anti-CD19 chimeric antigen receptor.
In various aspects, the host cell may be a T lymphocyte or a
natural killer (NK) cell.
[0020] The invention further provides methods for using the
anti-CD19 chimeric receptors. In one aspect, a method is provided
for enhancing T lymphocyte or natural killer cell activity of an
individual comprising introducing into said individual a T
lymphocyte or natural killer cell comprising the anti-CD19 chimeric
receptor. In another aspect, the invention provides a method for
treating an individual suffering from cancer comprising introducing
into said individual a T lymphocyte or natural killer cell
comprising the anti-CD19 chimeric receptor. In various embodiments
of this method, the cancer may be lung cancer, melanoma, breast
cancer, prostate cancer, colon cancer, renal cell carcinoma,
ovarian cancer, neuroblastoma, rhabdomyosarcoma, leukemia and
lymphoma, small cell lung cancer, Hodgkin's lymphoma, and or
childhood acute lymphoblastic leukemia. In some embodiments, the
cancer may be of B cell origin. In certain aspects, the cancer may
be B-lineage acute lymphoblastic leukemia, B-cell chronic
lymphocytic leukemia or B-cell non-Hodgkin's lymphoma.
[0021] The invention further provides a nucleic acid molecule
encoding an anti-CD19 chimeric receptor that comprises an
antigen-binding domain, a transmembrane domain, a costimulatory
signaling region comprising the signaling domain of the 4-1BB
receptor. In a specific embodiment, the anti-CD19 chimeric receptor
is encoded by the nucleic acid sequence of SEQ ID No: 5. In another
specific embodiment, the anti-CD19 chimeric receptor is encoded by
the nucleic acid sequence of SEQ ID No: 19. In one embodiment, the
anti-CD19 chimeric receptor comprises the amino acid sequence of
SEQ ID No: 6. In another embodiment, the anti-CD19 chimeric
receptor comprises the amino acid sequence of SEQ ID No: 20. In
certain embodiments, the chimeric receptor comprises a CD8.alpha.
signaling peptide which is encoded by the nucleic acid sequence of
SEQ ID No: 7. In another embodiment, the anti-CD19 chimeric
receptor comprises a CD8.alpha. signaling peptide comprising the
amino acid sequence of SEQ ID No: 8. In certain embodiments, the
antigen-binding fragment is a Fab or an scFv. In a specific
embodiment, the antigen-binding domain is an anti-CD19 scFv encoded
by SEQ ID No: 9. In certain embodiments, the antigen-binding domain
is an anti-CD19 scFv comprising the amino acid sequence of SEQ ID
No: 10. In a specific embodiment, the extracellular domain contains
the anti-CD19 single chain variable fragment domain described in
Nicholson I C, et al., Mol Immunol 34:1157-1165 (1997) plus the 21
amino acid signal peptide of CD8.alpha..
[0022] In certain embodiments, the 4-1BB signaling domain is
encoded by the nucleic acid sequence of SEQ ID No: 15. In certain
embodiments, the 4-1BB signaling domain comprises the amino acid
sequence of SEQ ID No: 16. In certain embodiments, the CD3.zeta.
signaling domain is encoded by the nucleic acid sequence of SEQ ID
No: 17 or SEQ ID No:22. In certain embodiments, the CD3.zeta.
signaling domain comprises the amino acid sequence of SEQ ID No: 18
or SEQ ID No. 22.
[0023] The invention further provides a vector comprising a nucleic
acid sequence encoding an anti-CD19 chimeric receptor, wherein the
chimeric receptor comprises an antigen-binding domain, a 4-1BB
costimulatory signaling region, and a CD3.zeta. signaling domain.
In some embodiments, the vector comprises a nucleic acid sequence
of SEQ ID No: 5. In some embodiments, the vector encodes a chimeric
receptor having the amino acid sequence of SEQ ID No: 6.
[0024] The invention further provides host cells comprising a
nucleic acid sequence encoding an anti-CD19 chimeric receptor
comprising an antigen-binding domain, a transmembrane domain, a
4-1BB costimulatory signaling region, and a CD3.zeta. signaling
domain. In one embodiment, the cell comprises a chimeric receptor
that comprises CD3.zeta. signaling domain encoded by the nucleic
acid sequence of SEQ ID No: 17 or SEQ ID No: 21. In certain
embodiments, the cell comprise a chimeric receptor that comprises a
CD3.zeta. signaling domain comprising the amino acid sequence of
SEQ ID No: 18 or SEQ ID No: 22. In one embodiment, the anti-CD19
chimeric receptor is encoded by the nucleic acid sequence of SEQ ID
No: 5 or SEQ ID No: 19. In another embodiment, the cell comprises a
chimeric receptor comprising the amino acid sequence of SEQ ID No:
6 or SEQ ID No: 20. In some embodiments, the cell may be a T cell
or a natural killer (NK) cell. In certain embodiments, the vector
is a retroviral vector. In one embodiment, the host cell is a T
lymphocyte. In other specific embodiments, the host cell is an
autologous cell. In yet other embodiments, the host cell is
isolated from a patient having a cancer of B cell origin. In
certain embodiments, the host cell is an autologous T lymphocyte.
In other embodiments the autologous T lymphocyte is derived from a
blood or tumor sample of a patient having a cancer of B cell origin
and activated and expanded in vitro. In another embodiment, the
host cell is isolated from a patient having lymphoblastic leukemia,
B-lineage acute lymphoblastic leukemia, B-cell chronic lymphocytic
leukemia or B-cell non-Hodgkin's lymphoma. In another embodiment,
the isolated host cell is isolated from a patient having lung
cancer, melanoma, breast cancer, prostate cancer, colon cancer,
renal cell carcinoma, ovarian cancer, neuroblastoma,
rhabdomyosarcoma, leukemia and lymphoma, acute lymphoblastic
leukemia, small cell lung cancer, Hodgkin's lymphoma, or childhood
acute lymphoblastic leukemia. In another embodiment, the host cell
is an autologous T lymphocyte is derived from a blood or tumor
sample of a patient having a cancer of B cell origin and activated
and expanded in vitro.
[0025] The invention further provides methods for using the
chimeric receptors of the invention. In one embodiment, a method is
provided for enhancing a T lymphocyte or an NK cell activity in a
mammal comprising introducing into the mammal a T lymphocyte or NK
cell, which comprises a chimeric receptor comprising: (a) an
extracellular ligand-binding domain comprising an anti-CD19 single
chain variable fragment (scFv) domain, (b) a hinge and
transmembrane domain, and (c) a cytoplasmic domain comprising a
4-1BB signaling domain and a CD3.zeta. signaling domain comprising
the amino acid sequence of SEQ ID No. 18 or SEQ ID No. 22.
[0026] In another embodiment the invention provides a method for
treating a mammal suffering from cancer comprising introducing into
the mammal a T lymphocyte or an NK cell, which T lymphocyte or NK
cell comprises a chimeric receptor comprising: (a) an extracellular
ligand-binding domain comprising an anti-CD 19 scFv domain; (b) a
hinge region and transmembrane domain of CD8.alpha.; and (c) a
cytoplasmic domain comprising a signaling domain of 4-1BB and a
CD3.zeta. signaling domain comprising the amino acid sequence of
SEQ ID No. 18 or SEQ ID No. 22.
[0027] In yet another embodiment the invention provides a a method
for stimulating a T cell-mediated immune response to a target cell
population or tissue in a mammal comprising administering an
effective amount of a cell genetically modified to express an
anti-CD19 chimeric receptor which comprises an antigen-binding
domain, a 4-1BB costimulatory signaling region, and a CD3.zeta.
signaling domain comprising the amino acid sequence of SEQ ID No.
18 or SEQ ID No. 22.
[0028] In another embodiment, a method of providing an anti-tumor
immunity in a mammal is provided, the method comprising
administering to the mammal an effective amount of a cell
genetically modified to express an anti-CD19 chimeric receptor
comprising an antigen-binding domain, a 4-1BB costimulatory
signaling region, and a CD3.zeta. signaling domain comprising the
amino acid sequence of SEQ ID No. 18 or SEQ ID No. 22, thereby
providing an antitumor immunity in the mammal.
[0029] In another embodiment, a method is provided for treating a
mammal having a disease, disorder or condition associated with an
elevated expression of a tumor antigen is provided comprising
administering to the mammal an effective amount of a cell
genetically modified to express an anti-CD19 chimeric antigen which
comprises an antigen-binding domain, a 4-1BB costimulatory
signaling region, and a CD3.zeta. signaling domain comprising the
amino acid sequence of SEQ ID No. 18 or SEQ ID No. 22. In one
embodiment of this method, the cell may be an autologous
T-cell.
[0030] In another embodiment, a method of generating a persisting
population of genetically engineered T cells in a human diagnosed
with cancer is provided, the method comprising administering to the
human a T cell genetically engineered to express an anti-CD19
chimeric receptor which comprises an antigen-binding domain, a
4-1BB costimulatory signaling region, and a CD3.zeta. signaling
domain comprising the amino acid sequence of SEQ ID No. 18 or SEQ
ID No. 22, wherein a population of genetically engineered T cells
persists in the human for at least one month after
administration.
[0031] In yet another embodiment, a method for expanding a
population of genetically engineered T cells in a human diagnosed
with cancer is provided, the method comprising administering to the
human a T cell genetically engineered to express an anti-CD19
chimeric receptor comprising an antigen-binding domain, a 4-1BB
costimulatory signaling region, and a CD3.zeta. signaling domain
comprising the amino acid sequence of SEQ ID No. 18 or SEQ ID No.
22, wherein the administered genetically engineered T cell produces
a population of progeny T cells in the human.
[0032] In each of the methods provided herein, the anti-CD19
chimeric receptor may be encoded by the nucleic acid sequence of
SEQ ID No: 5. In some embodiments, the anti-CD19 chimeric receptor
may comprise the amino acid sequence of SEQ ID No: 6. In another
embodiment, the anti-CD19 chimeric receptor comprises the amino
acid sequence of SEQ ID No: 20. In certain embodiments, the
chimeric receptor comprises a CD8.alpha. signaling peptide which is
encoded by the nucleic acid sequence of SEQ ID No: 7. In another
embodiment, the anti-CD19 chimeric receptor comprises a CD8.alpha.
signaling peptide comprising the amino acid sequence of SEQ ID No:
8. In some embodiments, the antigen-binding domain is an anti-CD19
scFv encoded by SEQ ID No: 9. In certain embodiments, the
antigen-binding domain is an anti-CD19 scFv comprising the amino
acid sequence of SEQ ID No: 10. In a specific embodiment, the
extracellular domain contains the anti-CD19 single chain variable
fragment domain described in Nicholson I C, et al., Mol Immunol
34:1157-1165 (1997) plus the 21 amino acid signal peptide of
CD8.alpha..
[0033] In certain embodiments, the 4-1BB signaling domain is
encoded by the nucleic acid sequence of SEQ ID No: 15. In certain
embodiments, the 4-1BB signaling domain comprises the amino acid
sequence of SEQ ID No: 16. In certain embodiments, the CD3.zeta.
signaling domain is encoded by the nucleic acid sequence of SEQ ID
No: 17 or SEQ ID No:22. In certain embodiments, the CD3.zeta.
signaling domain comprises the amino acid sequence of SEQ ID No: 18
or SEQ ID No. 22.
6. DESCRIPTION OF THE SEQUENCE LISTING
[0034] SEQ ID No. 1 is the nucleotide sequence for human 4-1BB
mRNA. The coding sequence for the human 4-1BB protein begins at
position 129 and ends at position 893.
[0035] SEQ ID No. 2 is the amino acid sequence of human 4-1BB. The
signaling domain begins at position 214 and ends at position
255.
[0036] SEQ. ID. No. 3 is the nucleotide sequence for murine 4-1BB
mRNA. The coding sequence for the murine 4-1BB protein begins at
position 146 and ends at position 916.
[0037] SEQ ID. No. 4 is the amino acid sequence of murine 4-1BB.
The signaling domain begins at position 209 and ends at position
256.
[0038] SEQ ID No. 5 is a nucleotide sequence that encodes an
anti-CD19-BB-.zeta. chimeric receptor.
[0039] SEQ. ID. No. 6 is an amino acid sequence of an
anti-CD19-BB-.zeta. chimeric receptor.
[0040] SEQ. ID. No. 7 is a nucleic acid sequence that encodes a
CD8.alpha. signal peptide.
[0041] SEQ. ID. No. 8 is an amino acid sequence of a CD8.alpha.
signal peptide.
[0042] SEQ. ID. No. 9 is a nucleic acid sequence that encodes an
anti-CD19 scFv.
[0043] SEQ. ID. No. 10 is an amino acid sequence of an anti-CD 19
scFv.
[0044] SEQ. ID. No. 11 is a nucleotide sequence that encodes a
CD8.alpha. hinge.
[0045] SEQ. ID. No. 12 is an amino acid sequence of an CD8.alpha.
hinge.
[0046] SEQ ID No. 13 is a nucleotide sequence that encodes a
CD8.alpha. transmembrane region.
[0047] SEQ ID No. 14 is an amino acid sequence of a CD8.alpha.
transmembrane region.
[0048] SEQ ID No. 15 is a nucleotide sequence that encodes a 4-1BB
signaling domain.
[0049] SEQ ID No. 16 is an amino acid sequence of a 4-1BB signaling
domain.
[0050] SEQ ID No. 17: is a nucleotide sequence that encodes a
CD3.zeta. signaling domain SEQ ID No. 18: is an amino acid sequence
of a CD3.zeta. signaling domain.
[0051] SEQ ID No. 19 is a nucleotide sequence that encodes an
anti-CD19-BB-.zeta. chimeric receptor.
[0052] SEQ ID No. 20 is an amino acid sequence of an
anti-CD19-BB-.zeta. chimeric receptor.
[0053] SEQ ID No. 21: is a nucleotide sequence that encodes a
CD3.zeta. signaling domain SEQ ID No. 22: is an amino acid sequence
of a CD3.zeta. signaling domain SEQ ID No. 22: is an amino acid
sequence of a CD3.zeta. signaling domain
7. DESCRIPTION OF THE FIGURES
[0054] FIG. 1 is a schematic representation of the CD19-truncated,
CD19-.zeta., CD19-28-.zeta. and CD19-BB-.zeta. receptor
constructs.
[0055] FIG. 2 shows the percent of CD19-positive leukemia cell
recovery in four different cell lines (380, 697, KOPN-57bi and
OP-1) after 24 hours of culture with NK cells with or without a
chimeric receptor at a 1:1 ratio relative to cultures with no NK
cells. The bars represent each of the 4 cell lines that are
co-cultured with NK cells containing either "vector" which is
MSCV-IRES GFP only; "trunc." which is vector containing truncated
anti-CD19; "c" which is vector containing anti-CD19-CD3.zeta.; "28
.zeta." which is vector containing anti-CD19-CD28.alpha.-CD3.zeta.;
or "BB-.zeta." which is vector containing anti-CD19-4-1BB
intracellular domain-CD3.zeta.. This figure shows that chimeric
receptors confer anti-ALL activity to NK cells which is improved by
the addition of the co-stimulatory molecules CD28 or 4-1BB.
8. DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0056] 4-1BB: The term "4-1BB" refers to a membrane receptor
protein also termed CD137, which is a member of the tumor necrosis
factor receptor (TNFR) superfamily expressed on the surface of
activated T-cells as a type of accessory molecule [Kwon et al.,
Proc. Natl. Acad. Sci. USA 86:1963 (1989); Pollok et al., J.
Immunol. 151:771 (1993)]. 4-1BB has a molecular weight of 55 kDa,
and is found as a homodimer. It has been suggested that 4-1BB
mediates a signal transduction pathway from outside of the cell to
inside [Kim et al., J. Immunol. 151:1255 (1993)].
[0057] A human 4-1BB gene (SEQ ID NO:1) was isolated from a cDNA
library made from activated human peripheral T-cell mRNA [Goodwin
et al., Eur. J. Immunol. 23:2631 (1993);]. The amino acid sequence
of human 4-1BB (SEQ ID NO: 2) shows 60% homology to mouse 4-1BB
(SEQ ID NO:4)[Kwon et al., Proc. Natl. Acad. Sci. USA 86:1963
(1989); Gen Bank No: NM.sub.--011612] which indicates that the
sequences are highly conserved. As mentioned supra, 4-1BB belongs
to the TNFR superfamily, along with CD40, CD27, TNFR-I, TNFR-II,
Fas, and CD30 [Alderson et al., Eur. J. Immunol. 24:2219 (1994)].
When a monoclonal antibody is bound to 4-1BB expressed on the
surface of mouse T-cells, anti-CD3 T-cell activation is increased
many fold [Pollok et al., J. Immunol. 150:771 (1993)].
[0058] 4-1BB binds to a high-affinity ligand (4-1BB, also termed
CD137L) expressed on several antigen-presenting cells such as
macrophages and activated B cells [Pollok et al., J. Immunol.
150:771 (1993) Schwarz et al., Blood 85:1043 (1995)). The
interaction of 4-1BB and its ligand provides a co-stimulatory
signal leading to T cell activation and growth [Goodwin et al.,
Eur. J. Immunol. 23:2631 (1993); Alderson et al., Eur. J. Immunol.
24:2219 (1994); Hurtado et al., J. Immunol. 155:3360 (1995);
Pollock et al., Eur. J. Immunol. 25:488 (1995); DeBenedette et al.,
J. Exp. Med. 181:985 (1995)]. These observations suggest an
important role for 4-1BB in the regulation of T cell-mediated
immune responses [Ignacio et al., Nature Med. 3:682 (1997)].
[0059] 4-1BB ligand (CD137L) is claimed and described in U.S. Pat.
No. 5,674,704.
[0060] The term IL-15 (interleukin 15) refers to a cytokine that
stimulates NK cells [Fehniger T A, Caligiuri M A. Blood 97(1):14-32
(2001)]. It has become apparent that IL-15 presented through
cell-to-cell contact has a higher NK stimulating activity than
soluble IL-15 [Dubois S, et al., Immunity 17(5):537-547 (2002);
Kobayashi H, et al., Blood (2004) PMID: 15367431; Koka R, et al., J
Immunol 173(6):3594-3598 (2004); Burkett P R, et al., J Exp Med
200(7):825-834 (2004)]. To express membrane-bound IL-15 a construct
consisting of human IL-15 mature peptide (NM.sub.--172174) was
fused to the signal peptide and transmembrane domain of human
CD8.alpha..
[0061] To specifically or preferentially expand NK cells means to
culture a mixed population of cells that contains a small number of
NK cells so that the NK cells proliferate to numbers greater than
other cell types in the population.
[0062] To activate T cells and NK cells means to induce a change in
their biologic state by which the cells express activation markers,
produce cytokines, proliferate and/or become cytotoxic to target
cells. All these changes can be produced by primary stimulatory
signals. Co-stimulatory signals amplify the magnitude of the
primary signals and suppress cell death following initial
stimulation resulting in a more durable activation state and thus a
higher cytotoxic capacity.
[0063] The terms T-cell and T lymphocyte are interchangeable and
used synonymously herein.
[0064] The term "chimeric receptor" as used herein is defined as a
cell-surface receptor comprising an extracellular ligand binding
domain, a transmembrane domain and a cytoplasmic co-stimulatory
signaling domain in a combination that is not naturally found
together on a single protein. This particularly includes receptors
wherein the extracellular domain and the cytoplasmic domain are not
naturally found together on a single receptor protein. The chimeric
receptors of the present invention are intended primarily for use
with T cells and natural killer (NK) cells.
[0065] The term "host cell" means any cell of any organism that is
selected, modified, transformed, grown, used or manipulated in any
way, for the production of a substance by the cell, for example the
expression by the cell of a gene, a DNA or RNA sequence, a protein
or an enzyme. Host cells of the present invention include T cells
and NK cells that contain the DNA or RNA sequences encoding the
chimeric receptor and express the chimeric receptor on the cell
surface. Host cells may be used for enhancing T lymphocyte
activity, NK cell activity, treatment of cancer, and treatment of
autoimmune diseases.
[0066] The terms "express" and "expression" mean allowing or
causing the information in a gene or DNA sequence to become
manifest, for example producing a protein by activating the
cellular functions involved in transcription and translation of a
corresponding gene or DNA sequence. A DNA sequence is expressed in
or by a cell to form an "expression product" such as a protein. The
expression product itself, e.g. the resulting protein, may also be
said to be "expressed" by the cell. An expression product can be
characterized as intracellular, extracellular or transmembrane. The
term "intracellular" means something that is inside a cell. The
term "extracellular" means something that is outside a cell. The
term transmembrane means something that has an extracellular domain
outside the cell, a portion embedded in the cell membrane and an
intracellular domain inside the cell.
[0067] The term "transfection" means the introduction of a foreign
nucleic acid into a cell using recombinant DNA technology. The term
"transformation" means the introduction of a "foreign" (i.e.
extrinsic or extracellular) gene, DNA or RNA sequence to a host
cell, so that the host cell will express the introduced gene or
sequence to produce a desired substance, typically a protein or
enzyme coded by the introduced gene or sequence. The introduced
gene or sequence may also be called a "cloned" or "foreign" gene or
sequence, may include regulatory or control sequences, such as
start, stop, promoter, signal, secretion, or other sequences used
by a cell's genetic machinery. The gene or sequence may include
nonfunctional sequences or sequences with no known function. A host
cell that receives and expresses introduced DNA or RNA has been
"transformed" and is a "transformant" or a "clone." The DNA or RNA
introduced to a host cell can come from any source, including cells
of the same genus or species as the host cell, or cells of a
different genus or species.
[0068] The term "transduction" means the introduction of a foreign
nucleic acid into a cell using a viral vector.
[0069] The terms "vector", "cloning vector" and "expression vector"
mean the vehicle by which a DNA or RNA sequence (e.g. a foreign
gene) can be introduced into a host cell, so as to transform the
host and promote expression (e.g. transcription and translation) of
the introduced sequence. Vectors include plasmids, phages, viruses,
etc.
[0070] A solid support means any surface capable of having an agent
attached thereto and includes, without limitation, metals, glass,
plastics, polymers, particles, microparticles, co-polymers,
colloids, lipids, lipid bilayers, cell surfaces and the like.
Essentially any surface that is capable of retaining an agent bound
or attached thereto. A prototypical example of a solid support used
herein, is a particle such as a bead.
[0071] The term "substantially free of" means a population of
cells, e.g. NK cells, that is at least 50% free of non-NK cells, or
in certain embodiments at least 60, 70, 80, 85, or 90% free of
non-NK cells.
[0072] A "co-stimulatory signal" refers to a signal, which in
combination with a primary signal, such as TCR/CD3 ligation, leads
to NK cell proliferation and/or upregulation or downregulation of
key molecules.
DESCRIPTION OF THE INVENTION
[0073] In accordance with the present invention there may be
employed conventional molecular biology, microbiology, and
recombinant DNA techniques within the skill of the art. Such
techniques are explained fully in the literature. See, e.g.,
Sambrook et al, "Molecular Cloning: A Laboratory Manual" (1989);
"Current Protocols in Molecular Biology" Volumes [-III [Ausubel, R.
M., ed. (1994)]; "Cell Biology: A Laboratory Handbook" Volumes
I-III [J. E. Celis, ed. (1994))]; "Current Protocols in Immunology"
Volumes I-III [Coligan, J. E., ed. (1994)]; "Oligonucleotide
Synthesis" (M. J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.
D. Haines & S. J. Higgins eds. (1985)]; "Transcription And
Translation" [B. D. Haines & S. J. Higgins, eds. (1984)];
"Animal CellCulture" [R. I. Freshney, ed. (1986)]; "Immobilized
Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical
Guide To Molecular Cloning" (1984); CURRENT PROTOCOLS IN IMMUNOLOGY
Q. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and
W. Strober, eds., 1991); ANNUAL REVIEW OF IMMUNOLOGY; as well as
monographs in journals such as ADVANCES IN IMMUNOLOGY. All patents,
patent applications, and publications mentioned herein are hereby
incorporated herein by reference.
[0074] Primary T cells expressing chimeric receptors specific for
tumor or viral antigens have considerable therapeutic potential as
immunotherapy reagents. Unfortunately, their clinical value is
limited by their rapid loss of function and failure to expand in
vivo, presumably due to the lack of co-stimulator molecules on
tumor cells and the inherent limitations of signaling exclusively
through the chimeric receptor.
[0075] The chimeric receptors of the present invention overcome
this limitation wherein they have the capacity to provide both the
primary effector activity and the co-stimulatory activity upon
binding of the receptor to a single ligand. For instance, binding
of the anti-CD19-BB-.zeta. receptor to the CD19 ligand provides not
only the primary effector function, but also a proliferative and
cytolytic effect.
[0076] T cells transduced with anti-CD19 chimeric receptors of the
present invention which contain co-stimulatory molecules have
remarkable anti-ALL capacity. However, the use of allogenic
receptor-modified T cells after hematopoietic cell transplantation
might carry the risk of severe graft-versus-host disease (GvHD). In
this setting, the use of CD3-negative NK cells is attractive
because they are not expected to cause GvHD.
[0077] Studies suggest an anti-tumor effect of NK cells and Zeis et
al., Br J Haematol 96: 757-61 (1997) have shown in mice that NK
cells contribute to a graft-versus-leukemia effect, without
inducing GvHD.
[0078] Expanding NK cells which can then be transfected with
chimeric receptors according to this method represents another
aspect of the present invention.
[0079] The chimeric receptors of the present invention comprise an
extracellular domain, a transmembrane domain and a cytoplasmic
domain. The extracellular domain and transmembrane domain can be
derived from any desired source for such domains.
[0080] As described in U.S. Pat. Nos. 5,359,046, 5,686,281 and
6,103,521, the extracellular domain may be obtained from any of the
wide variety of extracellular domains or secreted proteins
associated with ligand binding and/or signal transduction. The
extracellular domain may be part of a protein which is monomeric,
homodimeric, heterodimeric, or associated with a larger number of
proteins in a non-covalent complex. In particular, the
extracellular domain may consist of an Ig heavy chain which may in
turn be covalently associated with Ig light chain by virtue of the
presence of CH1 and hinge regions, or may become covalently
associated with other Ig heavy/light chain complexes by virtue of
the presence of hinge, CH2 and CH3 domains. In the latter case, the
heavy/light chain complex that becomes joined to the chimeric
construct may constitute an antibody with a specificity distinct
from the antibody specificity of the chimeric construct. Depending
on the function of the antibody, the desired structure and the
signal transduction, the entire chain may be used or a truncated
chain may be used, where all or a part of the CH1, CH2, or CH3
domains may be removed or all or part of the hinge region may be
removed.
[0081] Wherein an antitumor chimeric receptor is utilized, the
tumor may be of any kind as long as it has a cell surface antigen
which may be recognized by the chimeric receptor. In a specific
embodiment, the chimeric receptor may be for any cancer for which a
specific monoclonal antibody exists or is capable of being
generated. In particular, cancers such as neuroblastoma, small cell
lung cancer, melanoma, ovarian cancer, renal cell carcinoma, colon
cancer, Hodgkin's lymphoma, and childhood acute lymphoblastic
leukemia have antigens specific for the chimeric receptors.
[0082] The transmembrane domain may be contributed by the protein
contributing the multispecific extracellular inducer clustering
domain, the protein contributing the effector function signaling
domain, the protein contributing the proliferation signaling
portion, or by a totally different protein. For the most part it
will be convenient to have the transmembrane domain naturally
associated with one of the domains. In some cases it will be
desirable to employ the transmembrane domain of the .zeta., .eta.
or Fc.epsilon.R1.gamma. chains which contain a cysteine residue
capable of disulfide bonding, so that the resulting chimeric
protein will be able to form disulfide linked dimers with itself,
or with unmodified versions of the .zeta., .eta. or
Fc.epsilon.R1.gamma. chains or related proteins. In some instances,
the transmembrane domain will be selected or modified by amino acid
substitution to avoid binding of such domains to the transmembrane
domains of the same or different surface membrane proteins to
minimize interactions with other members of the receptor complex.
In other cases it will be desirable to employ the transmembrane
domain of .zeta., .eta., Fc.epsilon.R1--.gamma. and -.beta., MB1
(Ig.alpha.), B29 or CD3-.gamma., .zeta., or .epsilon., in order to
retain physical association with other members of the receptor
complex.
[0083] The cytoplasmic domain of the chimeric receptors of the
invention will comprise the 4-1BB signaling domain by itself or
combined with any other desired cytoplasmic domain(s) useful in the
context of this chimeric receptor type. In a most preferred
embodiment of the invention the extracellular domain comprises a
single chain variable domain of an anti-CD19 monoclonal antibody,
the transmembrane domain comprises the hinge and transmembrane
domain of CD8.alpha., and the cytoplasmic domain comprises the
signaling domain of CD3.zeta. and the signaling domain of 4-1BB.
The extracellular domain of the preferred embodiment contains the
anti-CD19 monoclonal antibody which is described in Nicholson I C,
et al., Mol Immunol 34:1157-1165 (1997) plus the 21 amino acid
signal peptide of CD8a (translated from 63 nucleotides at positions
26-88 of GenBank Accession No. NM.sub.--001768). The CD8.alpha.
hinge and transmembrane domain consists of 69 amino acids
translated from the 207 nucleotides at positions 815-1021 of
GenBank Accession No. NM.sub.--001768. The CD3.zeta. signaling
domain of the preferred embodiment contains 112 amino acids
translated from 339 nucleotides at positions 1022-1360 of GenBank
Accession No. NM.sub.--000734.
[0084] Antigen-specific cells can be expanded in vitro for use in
adoptive cellular immunotherapy in which infusions of such cells
have been shown to have anti-tumor reactivity in a tumor-bearing
host. The compositions and methods of this invention can be used to
generate a population of T lymphocyte or NK cells that deliver both
primary and co-stimulatory signals for use in immunotherapy in the
treatment of cancer, in particular the treatment of lung cancer,
melanoma, breast cancer, prostate cancer, colon cancer, renal cell
carcinoma, ovarian cancer, neuroblastoma, rhabdomyosarcoma,
leukemia and lymphoma. Immunotherapeutics, generally, rely on the
use of immune effector cells and molecules to target and destroy
cancer cells. The effector may be a lymphocyte carrying a surface
molecule that interacts, either directly or indirectly, with a
tumor cell target. Various effector cells include cytotoxic T cells
and NK cells. The compositions and methods described in the present
invention may be utilized in conjunction with other types of
therapy for cancer, such as chemotherapy, surgery, radiation, gene
therapy, and so forth.
[0085] In adoptive immunotherapy, the patient's circulating
lymphocytes, or tumor infiltrated lymphocytes, are isolated in
vitro, activated by lymphokines such as IL-2 or transduced with
genes for tumor necrosis, and readministered [Rosenberg et al., N.
Engl. J. Med. 319:1767 (1988)]. To achieve this, one would
administer to an animal, or human patient, an immunologically
effective amount of activated lymphocytes genetically modified to
express a tumor-specific chimeric receptor gene as described
herein. The activated lymphocytes will most preferably be the
patient's own cells that were earlier isolated from a blood or
tumor sample and activated and expanded in vitro. In aspects of the
present invention T lymphocytes or NK cells from a patient having a
cancer of B cell origin such as lymphoblastic leukemia, B-cell
chronic lymphocytic leukemia or B-cell non-Hodgkin's lymphoma would
be isolated and transduced with the CD19-BB-.zeta. polynucleotide
so that a chimeric receptor containing 4-1BB in the cytoplasmic
domain is express on the cell surface of the T cell or NK cell. The
modified cells would then be readministered into the patient to
target and kill the tumor cells.
[0086] As shown in one Example infra, primary T-cells were
transduced with the anti-CD19-BB-.zeta. receptor of the present
invention. One week after transduction the T-cells had expanded 3-4
fold in contrast to cells that were transduced with a chimeric
receptor that lacked 4-1BB. After 3 weeks in culture the T-cells
had expanded by more than 16-fold.
[0087] T-cells that were transduced with the anti-CD19-BB-.zeta.
receptor and cultured in 200 IU/mL of IL-2 for two weeks, then
removed from IL-2 and exposed to irradiated OP-1 cells underwent
apoptosis. However, cells cultured in 10 IU/mL of IL-2 and exposed
to irradiated OP-1 cells for two weeks after transduction remained
viable. T-cells that were transduced with CD19 chimeric receptors
that lacked 4-1BB underwent apoptosis under these same conditions.
These results show that 4-1BB co-stimulation confers a survival
advantage on lymphocytes, which overcomes a major obstacle with
current chimeric receptors used in immunotherapy.
[0088] To determine if T-cells transduced with the
anti-CD19-BB-.zeta. receptor exhibited cytotoxic activity under
conditions necessary for immunotherapy, their cytotoxic activity at
low effector:target (E:T) ratios were measured. As described in the
Example infra, T-cells transduced with the anti-CD19-BB-.zeta.
receptor and control vectors were expanded in vitro for two weeks
and mixed with OP-1 cells at various E:T ratios (1:1, 0.1:1, and
0.01:1). Viable leukemic cells were counted after one week of
culture. T-cells expressing the anti-CD19-BB-.zeta. receptor
exhibited cytotoxic activity at the 1:1 and 0.1:1 ratios against
all CD19.sup.+ cell lines tested. The anti-CD19-BB-.zeta. receptor
was not effective at the 0.01:1 ratio. The CD19 chimeric receptor
that lacked 4-1BB showed cytotoxic activity at the 1:1 ratio, but
at the 0.1:1 ratio the results were inferior to the
anti-CD19-BB-.zeta. receptor.
[0089] A surprising result obtained with the anti-CD 19-BB-.zeta.
receptor was that the T-cells transduced with the receptor
exhibited cytotoxic activity toward CD19.sup.+ leukemic cells at a
ratio of 0.01:1 when the leukemic cells were co-cultured with bone
marrow-derived mesenchymal cells. This result shows that T-cells
transduced with the anti-CD19-BB-.zeta. receptor exhibit cytotoxic
activity in an environment critical for B-lineage leukemic cell
growth. Another unexpected result was that expression of the
anti-CD 19-BB-.zeta. receptor caused higher levels of TRAIL
stimulation.
[0090] Furthermore, IL-2, which causes CD8.sup.+ cells to expand
more vigorously, levels in cells expressing the anti-CD19-BB-.zeta.
receptor were higher than in cells expressing the other receptors
tested. These results further support the use of the
anti-CD19-BB-.zeta. receptor for immunotherapy.
Construction of the Anti-CD 19-BB-.zeta. Receptor
[0091] The present invention provides a chimeric receptor construct
which contains the signaling domain of 4-1BB and fragments thereof.
In a preferred embodiment of the invention, the genetic fragments
used in the chimeric receptor were generated using splicing by
overlapping extension by PCR(SOE-PCR), a technique useful for
generating hybrid proteins of immunological interest. [Warrens A N,
et al. Gene 20; 186: 29-35 (1997)]. Other procedures used to
generate the polynucleotides and vector constructs of the present
invention are well known in the art.
Transduction of T-Cells
[0092] As shown in the Examples, infra, a polynucleotide expressing
a chimeric receptor capable of providing both primary effector and
co-stimulatory activities was introduced into T-cells and NK cells
via retroviral transduction. References describing retroviral
transduction of genes are Anderson et al., U.S. Pat. No. 5,399,346;
Mann et al., Cell 33:153 (1983); Temin et al., U.S. Pat. No.
4,650,764; Temin et al., U.S. Pat. No. 4,980,289; Markowitz et al.,
J. Virol. 62:1120 (1988); Temin et al., U.S. Pat. No. 5,124,263;
International Patent Publication No. WO 95/07358, published Mar.
16, 1995, by Dougherty et al.; and Kuo et al., Blood 82:845 (1993).
International Patent Publication No. WO 95/07358 describes high
efficiency transduction of primary B lymphocytes.
Expansion of NK Cells
[0093] The present invention shows that human primary NK cells may
be expanded in the presence of a myeloid cell line that has been
genetically modified to express membrane bound IL-15 and 4-1BB
ligand (CD137L). A cell line modified in this way which does not
have MHC class I and II molecules is highly susceptible to NK cell
lysis and activates NK cells.
[0094] For example, K562 myeloid cells can be transduced with a
chimeric protein construct consisting of human IL-15 mature peptide
fused to the signal peptide and transmembrane domain of human
CD8.alpha. and GFP. Transduced cells can then be single-cell cloned
by limiting dilution and a clone with the highest GFP expression
and surface IL-15 selected. This clone can then be transduced with
human CD137L, creating a K562-mb15-137L cell line.
[0095] To preferentially expand NK cells, peripheral blood
mononuclear cell cultures containing NK cells are cultured with a
K562-mb15-137L cell line in the presence of 101 U/mL of IL-2 for a
period of time sufficient to activate and enrich for a population
of NK cells. This period can range from 2 to 20 days, preferably
about 5 days. Expanded NK cells may then be transduced with the
anti-CD19-BB-.zeta. chimeric receptor.
Administration of Activated T Cells and NK Cells
[0096] Methods of re-introducing cellular components are known in
the art and include procedures such as those exemplified in U.S.
Pat. Nos. 4,844,893 and 4,690,915. The amount of activated T cells
or NK cells used can vary between in vitro and in vivo uses, as
well as with the amount and type of the target cells. The amount
administered will also vary depending on the condition of the
patient and should be determined by considering all appropriate
factors by the practitioner.
[0097] Obtaining an enriched population of NK cells for use in
therapy has been difficult to achieve. Specific NK cell expansion
has been problematic to achieve with established methods, where
CD3+ T cells preferentially expand. Even after T cell depletion,
residual T cells typically become prominent after stimulation.
However, in accordance with the teachings of the present invention
NK cells may be preferentially expanded by exposure to cells that
lack or poorly express major histocompatibility complex I and/or II
molecules and which have been genetically modified to express
membrane bound IL-15 and 4-1BB ligand (CDI37L). Such cell lines
include, but are not necessarily limited to, K562 [ATCC, CCL 243;
Lozzio et al., Blood 45(3): 321-334 (1975); Klein et al., Int. J.
Cancer 18: 421-431 (1976)], and the Wilms tumor cell line HFWT.
[Fehniger T A, Caligiuri M A. Int Rev Immunol 20(3-4):503-534
(2001); Harada H, et al., Exp Hematol 32(7):614-621 (2004)], the
uterine endometrium tumor cell line HHUA, the melanoma cell line
HMV-II, the hepatoblastoma cell line HuH-6, the lung small cell
carcinoma cell lines Lu-130 and Lu-134-A, the neutoblastoma cell
lines NB 19 and N1369, the embryonal carcinoma cell line from
testis NEC 14, the cervix carcinoma cell line TCO-2, and the bone
marrow-metastated neuroblastoma cell line TNB 1 [Harada H., et al.,
Jpn. J. Cancer Res 93: 313-319 (2002)]. Preferably the cell line
used lacks or poorly expresses both MHC I and II molecules, such as
the K562 and HFWT cell lines.
[0098] A solid support may be used instead of a cell line. Such
supports will have attached on its surface at least one molecule
capable of binding to NK cells and inducing a primary activation
event and/or a proliferative response or capable of binding a
molecule having such an affect thereby acting as a scaffold. The
support may have attached to its surface the CD 137 ligand protein,
a CD137 antibody, the IL-15 protein or an IL-15 receptor antibody.
Preferably, the support will have IL-15 receptor antibody and CD137
antibody bound on its surface.
[0099] The invention is intended to include the use of fragments,
mutants, or variants (e.g., modified forms) of the IL-15 and/or
CD137 ligand proteins or antigens that retain the ability to induce
stimulation and proliferation of NK cells. A "form of the protein"
is intended to mean a protein that shares a significant homology
with the IL-15 or CD137 ligand proteins or antigen and is capable
of effecting stimulation and proliferation of NK cells. The terms
"biologically active" or "biologically active form of the protein,"
as used herein, are meant to include forms of the proteins or
antigens that are capable of effecting enhanced activated NK cell
proliferation. One skilled in the art can select such forms based
on their ability to enhance NK cell activation and proliferation
upon introduction of a nucleic acid encoding said proteins into a
cell line. The ability of a specific form of the IL-15 or CD137
ligand protein or antigen to enhance NK cell proliferation can be
readily determined, for example, by measuring cell proliferation or
effector function by any known assay or method.
[0100] Antigen-specific cells can be expanded in vitro for use in
adoptive cellular immunotherapy in which infusions of such cells
have been shown to have anti-tumor reactivity in a tumor-bearing
host. The compositions and methods of this invention can be used to
generate a population of NK cells that deliver both primary and
co-stimulatory signals for use in immunotherapy in the treatment of
cancer, in particular the treatment of lung cancer, melanoma,
breast cancer, prostate cancer, colon cancer, renal cell carcinoma,
ovarian cancer, neuroblastoma, rhabdomyosarcoma, leukemia and
lymphoma. The compositions and methods described in the present
invention may be utilized in conjunction with other types of
therapy for cancer, such as chemotherapy, surgery, radiation, gene
therapy, and so forth.
9. EXAMPLES
9.1 Example 1
Introduction
[0101] In approximately 20% of children and 65% of adults with
acute lymphoblastic leukemia (ALL), drug-resistant leukemic cells
survive intensive chemotherapy and cause disease recurrence. [Pui C
H et al, Childhood acute lymphoblastic leukemia--Current status and
future perspectives. Lancet Oncology 2:597-607 (2001); Verma A,
Stock W. Management of adult acute lymphoblastic leukemia: moving
toward a risk-adapted approach. Curr Opin Oncol 13:14-20T (2001)]
lymphocyte-based cell therapy should bypass cellular mechanisms of
drug resistance. Its potential clinical value for leukemia is
demonstrated by the association between T-cell-mediated
graft-versus-host disease (GvHD) and delay or suppression of
leukemia recurrence after allogeneic stem cell transplantation.
[Champlin R. T-cell depletion to prevent graft-versus-host disease
after bone marrow transplantation. Hematol Oncol Clin North Am
4:687-698 (1990); Porter D L, Antin J H. The graft-versus-leukemia
effects of allogeneic cell therapy. Annu Rev Med 50:369-86.:369-386
(1999); Appelbaum F R. Haematopoietic cell transplantation as
immunotherapy. Nature 411:385-389 (2001)] Manipulation of GvHD by
infusion of donor lymphocytes can produce a measurable
anti-leukemic effect. [Porter D L, et al. Induction of
graft-versus-host disease as immunotherapy for relapsed chronic
myeloid leukemia. N Engl J Med 330:100-106 (1994); Kolb H J, et al.
Graft-versus-leukemia effect of donor lymphocyte transfusions in
marrow grafted patients. Blood 6:2041-2050 (1995); Slavin S, et al.
Allogeneic cell therapy with donor peripheral blood cells and
recombinant human interleukin-2 to treat leukemia relapse after
allogeneic bone marrow transplantation. Blood 87:2195-2204 (1996);
Collins R H, et al. Donor leukocyte infusions in 140 patients with
relapsed malignancy after allogeneic bone marrow transplantation. J
Clin Oncol 15:433-444 (1997)] However, in patients with ALL this
effect is often limited, [Kolb H J, et al. Graft-versus-leukemia
effect of donor lymphocyte transfusions in marrow grafted patients.
Blood 86:2041-2050 (1995); Verdonck L F, et al. Donor leukocyte
infusions for recurrent hematologic malignancies after allogeneic
bone marrow transplantation: impact of infused and residual donor T
cells. Bone Marrow Transplant 22:1057-1063 (1998); Collins R H,
Jr., et al. Donor leukocyte infusions in acute lymphocytic
leukemia. Bone Marrow Transplant 26:511-516 (2000)] possibly
reflecting inadequate T-cell stimulation by leukemic
lymphoblasts.
[0102] T lymphocyte specificity can be redirected through
expression of chimeric immune receptors consisting of an
extracellular antibody-derived single-chain variable domain (scFv)
and an intracellular signal transduction molecule (e.g., the
signaling domain of CD3.zeta. or Fc.gamma.RIII). [Geiger T L,
Jyothi M D. Development and application of receptor-modified T
lymphocytes for adoptive immunotherapy. Transfus Med Rev 15:21-34
(2001); Schumacher T N. T-cell-receptor gene therapy. Nat Rev
Immunol. 2:512-519 (2002); Sadelain M, et al. Targeting tumours
with genetically enhanced T lymphocytes. Nat Rev Cancer 3:35-45
(2003)] Such T lymphocytes can be activated by cell surface
epitopes targeted by the scFv and can kill the epitope-presenting
cells. The first requirement to redirect T cells against ALL cells
is the identification of target molecules that are selectively
expressed by leukemic cells. In B-lineage ALL, CD19 is an
attractive target, because it is expressed on virtually all
leukemic lymphoblasts in almost all cases. [Campana D, Behm F G.
Immunophenotyping of leukemia. J Immunol Methods 243:59-75 (2000)]
It is not expressed by normal non-hematopoietic tissues, and among
hematopoietic cells, it is expressed only by B-lineage lymphoid
cells. [Campana D, Behm F G. Immunophenotyping of leukemia. J
Immunol Methods 243:59-75 (2000); Nadler L M, et al. B4, a human B
lymphocyte-associated antigen expressed on normal,
mitogen-activated, and malignant B lymphocytes. J Immunol
131:244-250 (1983)] Recent studies have shown that T-cells
expressing anti-CD19 scFv and CD3.zeta. signaling domain can
proliferate when mixed with CD19.sup.+ cells and can lyse
CD19.sup.+ target cells. [Cooper L J, et al. T-cell clones can be
rendered specific for CD19: toward the selective augmentation of
the graft-versus-B-lineage leukemia effect. Blood 101:1637-1644
(2003); Brentjens R J, et al. Eradication of systemic B-cell tumors
by genetically targeted human T lymphocytes co-stimulated by CD80
and interleukin-15. Nat Med 9:279-286 (2003)]
[0103] A prerequisite for the success of T-cell therapy is the
capacity of the engineered T lymphocytes to expand and produce a
vigorous and durable anti-leukemic response in vivo. The engagement
of the TCR, although necessary, is not sufficient to fully activate
T cells; a second signal, or co-stimulus, is also required.
[Liebowitz D N, et al. Costimulatory approaches to adoptive
immunotherapy. Curr Opin Oncol 10:533-541 (1998); Allison J P,
Lanier L L. Structure, function, and serology of the T-cell antigen
receptor complex Annu Rev Immunol 5:503-540 (1987); Salomon B,
Bluestone J A. Complexities of CD28/B7: CTLA-4 costimulatory
pathways in autoimmunity and transplantation. Annu Rev Immunol
19:225-52.:225-252 (2001)] This could be a major obstacle for
chimeric receptor-based therapy of B-lineage ALL, because B-lineage
leukemic lymphoblasts generally lack B7 molecules that bind to CD28
on T-lymphocytes and trigger the CD28-mediated co-stimulatory
pathway. [Cardoso A A, et al. Pre-B acute lymphoblastic leukemia
cells may induce T-cell anergy to alloantigen. Blood 88:41-48
(1996)] This limitation might be overcome by incorporating the
signal transduction domain of CD28 into chimeric receptors. [Eshhar
Z, et al. Functional expression of chimeric receptor genes in human
T cells. J Immunol Methods 2001; 248:67-76 (2001); Hombach A, et
al. Tumor-specific T cell activation by recombinant
immunoreceptors: CD3 zeta signaling and CD28 costimulation are
simultaneously required for efficient IL-2 secretion and can be
integrated into one combined CD28/CD3 zeta signaling receptor
molecule. J Immunol 167:6123-6131 (2001); Geiger T L, et al.
Integrated src kinase and costimulatory activity enhances signal
transduction through single-chain chimeric receptors in T
lymphocytes. Blood 98:2364-2371 (2001); Maher J, et al. Human
T-lymphocyte cytotoxicity and proliferation directed by a single
chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20:70-75 (2002)]
Murine T cells bearing such receptors have shown a greater capacity
to inhibit cancer cell growth and metastasis in mice than those
with chimeric receptors lacking this domain. [Haynes N M, et al.
Rejection of syngeneic colon carcinoma by CTLs expressing
single-chain antibody receptors codelivering CD28 costimulation. J
Immunol 169:5780-5786 (2002); Haynes N M, et al. Single-chain
antigen recognition receptors that costimulate potent rejection of
established experimental tumors. Blood 100:3155-3163 (2002)]
[0104] A second co-stimulatory pathway in T cells, independent of
CD28 signaling, is mediated by 4-1BB (CD137), a member of the tumor
necrosis factor (TNF) receptor family. [Sica G, Chen L. Modulation
of the immune response through 4-1BB. In: Habib N, ed. Cancer gene
therapy: past achievements and future challenges. New York: Kluwer
Academic/Plenum Publishers; 355-362 (2000)]-4-1BB stimulation
significantly enhances survival and clonal expansion of CD8+
T-lymphocytes, and CD8+ T-cell responses in a variety of settings,
including viral infection, allograft rejection, and tumor immunity.
[Shuford W W, et al. 4-1BB costimulatory signals preferentially
induce CD8+ T cell proliferation and lead to the amplification in
vivo of cytotoxic T cell responses. J Exp Med 186:47-55 (1997);
Melero I, et al. Monoclonal antibodies against the 4-1BB T-cell
activation molecule eradicate established tumors. Nat Med 3:682-685
(1997); Melero I, et al. Amplification of tumor immunity by gene
transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28
co-stimulatory pathway. Eur J Immunol 28:1116-1121 (1998);
Takahashi C, et al. Cutting edge: 4-1BB is a bona fide CD8 T cell
survival signal. J Immunol 162:5037-5040 (1999); Martinet 0, et al.
T cell activation with systemic agonistic antibody versus local
4-1BB ligand gene delivery combined with interleukin-12 eradicate
liver metastases of breast cancer. Gene Ther 9:786-792 (2002); May
K F, Jr., et al. Anti-4-1BB monoclonal antibody enhances rejection
of large tumor burden by promoting survival but not clonal
expansion of tumor-specific CD8+ T cells. Cancer Res 62:3459-3465
(2002)] However, the natural ligand of 4-1BB is weakly and
heterogeneously expressed in B-lineage ALL cells (C. Imai, D.
Campana, unpublished observations). Therefore, it is likely that
this important co-stimulatory signal, like CD28, can become
operational only if 4-1BB is added to chimeric receptors. However,
it is not known whether such receptors would help deliver effective
T-cell responses to cancer cells and, if so, whether these would be
equivalent to those elicited by receptors containing CD28.
[0105] We constructed a chimeric T-cell receptor specific for CD19
that contains a 4-1BB signaling domain. We determined whether T
cells transduced with these receptors could effectively destroy
B-lineage ALL cell lines and primary leukemic cells under culture
conditions that approximate the in vivo microenvironment where
leukemic cells grow. We compared the properties of T-cells
expressing the 4-1BB-containing receptor to those of T-cells
expressing an equivalent receptor lacking 4-1BB or containing CD28
instead.
Materials And Methods
Cells
[0106] Available in our laboratory were the human B-lineage ALL
cell line OP-1, developed from the primary leukemic cells of a
patient with newly diagnosed B-lineage ALL with the
t(9;22)(q34;q11) karyotype and the BCR-ABL gene fusion; [Manabe A,
et al. Interleukin-4 induces programmed cell death (apoptosis) in
cases of high-risk acute lymphoblastic leukemia. Blood 83:1731-1737
(1994)] the B-lineage ALL cell lines RS4;11, [Stong R C, et al.
Human acute leukemia cell line with the t(4;11) chromosomal
rearrangement exhibits B lineage and monocytic characteristics.
Blood 1985; 65:21-31 (1985)] and REH [Rosenfeld C, et al.
Phenotypic characterisation of a unique non-T, non-B acute
lymphoblastic leukaemia cell line. Nature 267:841-843 (1977)]; the
T-cell lines Jurkat [Schneider U, et al. Characterization of
EBV-genome negative "null" and "T" cell lines derived from children
with acute lymphoblastic leukemia and leukemic transformed
non-Hodgkin lymphoma. Int J Cancer 1977; 19:621-626 (1977)] and
CEM-C7 [Harmon J M, et al. Dexamethasone induces irreversible G1
arrest and death of a human lymphoid cell line. J Cell Physiol
98:267-278 (1979)]; and the myeloid cell lines K562 [Koeffler H P,
Golde D W. Acute myelogenous leukemia: a human cell line responsive
to colony-stimulating activity. Science 200:1153-1154 (1978)] and
U-937. [Sundstrom C, Nilsson K. Establishment and characterization
of a human histiocytic lymphoma cell line (U-937). Int J Cancer
1976; 17:565-577 (1976)] Cells were maintained in RPMI-1640 (Gibco,
Grand Island, N.Y.) with 10% fetal calf serum (FCS; BioWhittaker,
Walkersville, Md.) and antibiotics. Human adenocarcinoma HeLa cells
and embryonic kidney fibroblast 293T cells, maintained in DMEM
(MediaTech, Herndon, Va.) supplemented with 10% FCS and
antibiotics, were also used.
[0107] We used primary leukemia cells obtained from 5 patients with
newly diagnosed B-lineage ALL with the approval of the St. Jude
Children's Research Hospital Institutional Review Board and with
appropriate informed consent. The diagnosis of B-lineage ALL was
unequivocal by morphologic, cytochemical, and immunophenotypic
criteria; in each case, more than 95% of leukemic cells were
positive for CD19. Peripheral blood samples were obtained from 7
healthy adult donors. Mononuclear cells were collected from the
samples by centrifugation on a Lymphoprep density step (Nycomed,
Oslo, Norway) and were washed two times in phosphate-buffered
saline (PBS) and once in AIM-V medium (Gibco).
Plasmids
[0108] The plasmid encoding anti-CD19 scFv was obtained from Dr. I.
Nicholson (Child Health Research Institute, Adelaide, Australia).
[Nicholson I C, et al. Construction and characterisation of a
functional CD19 specific single chain Fv fragment for immunotherapy
of B lineage leukaemia and lymphoma. Mol Immunol 34:1157-1165
(1997)] The pMSCV-IRES-GFP, pEQPAM3(-E), and pRDF were obtained
from Dr. E. Vanin at our institution. Signal peptide, hinge and
transmembrane domain of CD8.alpha., and intracellular domains of
4-1BB, CD28, CD3.zeta. and CD19 were subcloned by polymerase chain
reaction (PCR) using a human spleen cDNA library (from Dr. G.
Neale, St. Jude Children's Research Hospital) as a template. FIG. 1
shows a schematic representation of the anti-CD19-.zeta.,
anti-CD19-BB-.zeta., anti-CD19-28-.zeta..and anti-CD19-truncated
(control) constructs. We used splicing by overlapping extension by
PCR(SOE-PCR) to assemble several genetic fragments. [Warrens A N,
et al. Splicing by overlap extension by PCR using asymmetric
amplification: an improved technique for the generation of hybrid
proteins of immunological interest. Gene 20; 186:29-35 (1997)] The
sequence of each genetic fragment was confirmed by direct
sequencing. The resulting expression cassettes were subcloned into
EcoRI and XhoI sites of MSCV-IRES-GFP.
[0109] To transduce CD19-negative K562 cells with CD19, we
constructed a MSCV-IRES-DsRed vector. The IRES and DsRed sequences
were subcloned from MSCV-IRES-GFP and pDsRedN1 (Clontech, Palo
Alto, Calif.), respectively, and assembled by SOE-PCR. The
IRES-DsRed cassette was digested and ligated into XhoI and NotI
sites of MSCV-IRES-GFP. The expression cassette for CD19 was
subsequently ligated into EcoRI and XhoI sites of MSCV-IRES-DsRed
vector.
Virus Production and Gene Transduction
[0110] To generate RD114-pseudotyped retrovirus, we used calcium
phosphate DNA precipitation to transfect 3.times.10.sup.6 293T
cells, maintained in 10-cm tissue culture dishes (Falcon, Becton
Dickinson, Franklin Lakes, N.J.) for 24 hours, with 8 .mu.g of one
of the vectors anti-CD19-.zeta., anti-CD19-BB-.zeta.,
anti-CD19-28-.zeta. or anti-CD19-truncated, 8 .mu.g of pEQ-PAM3(-E)
and 4 .mu.g of pRDF. After 24 hours, medium was replaced with
RPMI-1640 with 10% FCS and antibiotics. Conditioned medium
containing retrovirus was harvested 48 hours and 72 hours after
transfection, immediately frozen in dry ice, and stored at
-80.degree. C. until use. HeLa cells were used to titrate virus
concentration.
[0111] Peripheral blood mononuclear cells were incubated in a
tissue culture dish for 2 hours to remove adherent cells.
Non-adherent cells were collected and prestimulated for 48 hours
with 7 .mu.g/mL PHA-M (Sigma, St. Louis, Mo.) and 200 IU/mL human
IL-2 (National Cancer Institute BRB Preclinical Repository,
Rockville, Md.) in RPMI-1640 and 10% FCS. Cells were then
transduced as follows. A 14-mL polypropylene centrifuge tube
(Falcon) was coated with 0.5 mL of human fibronectin (Sigma)
diluted to 100 .mu.g/mL for 2 hours at room temperature and then
incubated with 2% bovine serum albumin (Sigma) for 30 minutes.
Prestimulated cells (2.times.10.sup.5) were resuspended in the
fibronectin-coated tube in 2-3 mL of virus-conditioned medium with
polybrene (4 .mu.g/mL; Sigma) and centrifuged at 2400.times.g for 2
hours. The multiplicity of infection (4 to 8) was identical in each
experiment comparing the activity of different chimeric receptors.
After centrifugation, cells were left undisturbed for 24 hours in a
humidified incubator at 37.degree. C., 5% CO.sub.2. The
transduction procedure was repeated on two successive days. Cells
were then washed twice with RPMI-1640 and maintained in RPMI-1640,
10% FCS, and 200 IU/mL of IL-2 until use.
[0112] A similar procedure was used to express chimeric receptors
in Jurkat cells, except that cells were not prestimulated. K562
cells expressing CD19 were created by resuspending 2.times.10.sup.5
K562 cells in 3 mL of MSCV-CD19-IRES-DsRed virus medium with 4
.mu.g/mL polybrene in a fibronectin-coated tube; the tube was
centrifuged at 2400.times.g for 2 hours and left undisturbed in an
incubator for 24 hours. Control cells were transduced with the
vector only. These procedures were repeated on 3 successive days.
After confirming CD19 and DsRed expression, cells were subjected to
single-cell sorting with a fluorescence-activated cell sorter
(MoFlo, Cytomation, Fort Collins, Colo.). The clones that showed
the highest expression of DsRed and CD19 and of DsRed alone were
selected for further experiments.
Detection of Chimeric Receptor Expression
[0113] Transduced Jurkat and peripheral blood cells were stained
with goat anti-mouse (Fab).sub.2 polyclonal antibody conjugated
with biotin (Jackson Immunoresearch, West Grove, Pa.) followed by
streptavidin conjugated to peridinin chlorophyll protein (PerCP;
Becton Dickinson, San Jose, Calif.). Patterns of CD4, CD8, and CD28
expression were also analyzed by using anti-CD4 and anti-CD28
conjugated to PE and anti-CD8 conjugated to PerCP (antibodies from
Becton Dickinson, and Pharmingen, San Diego, Calif.). Antibody
staining was detected with a FACScan flow cytometer (Becton
Dickinson).
[0114] For Western blotting, 2.times.10.sup.7 cells were lysed in 1
mL RIPA buffer (PBS, 1% Triton-X100, 0.5% sodium deoxycholate, 0.1%
SDS) containing 3 .mu.g/mL of pepstatin, 3 .mu.g/mL of leupeptin, 1
mM of PMSF, 2 mM of EDTA, and 5 .mu.g/mL of aprotinin. Centrifuged
lysate supernatants were boiled with an equal volume of loading
buffer with or without 0.1 M DTT, then were separated by SDS-PAGE
on a precast 12% acrylamide gel (BioRad, Hercules, Calif.). The
proteins were transferred to a PVDF membrane, which was incubated
with primary mouse anti-human CD3.zeta. monoclonal antibody (clone
8D3; Pharmingen), 1 .mu.g/mL for 12 hours at 4.degree. C. Membranes
were then washed, incubated with a 1:500 dilution of goat
anti-mouse IgG horseradish peroxidase-conjugated second antibody
for 1 hour, and developed by using the ECP kit (Pharmacia,
Piscataway, N.J.).
Changes in Gene Expression and Cytokine Production after Receptor
Ligation
[0115] Jurkat cells transduced with the chimeric receptors were
cocultured with OP-1 leukemic cells fixed with 0.5%
paraformaldehyde at an effector:target (E:T) ratio of 1:1. RNA was
extracted using Trizol Reagent (Invitrogen, Carlsbad, Calif.). Gene
expression of Jurkat cells was analyzed using HG-U133A GeneChip
microarrays (Affymetrix, Santa Clara, Calif.) as previously
described. [Yeoh E J, et al. Classification, subtype discovery, and
prediction of outcome in pediatric acute lymphoblastic leukemia by
gene expression profiling. Cancer Cell 2002; 1:133-143 (2002); Ross
M E, et al. Classification of pediatric acute lymphoblastic
leukemia by gene expression profiling. Blood. May 2003;
10.1182/blood-2003-01-0338 (2003)] Arrays were scanned using a
laser confocal scanner (Agilent, Palo Alto, Calif.) and analyzed
with Affymetrix Microarray suite 5.0. We used an arbitrary factor
of 2 or higher to define gene overexpression. IL-2, TNF-related
apoptosis-inducing ligand (TRAIL), OX40, IL-3 and .beta.-actin
transcripts were detected by semi-quantitative reverse
transcriptase-polymerase chain reaction (RT-PCR) using Jurkat cells
stimulated as above; primers were designed using the Primer3
software developed by the Whitehead Institute for Biomedical
Research.
[0116] For cytokine production, Jurkat cells and primary
lymphocytes (2.times.10.sup.5 in 200 .mu.l) expressing chimeric
receptors were stimulated with OP-1 cells at a 1:1 E:T ratio for 24
hours. Levels of IL-2 and IFN.gamma. in culture supernatants were
determined with a Bio-Plex assay (BioRad). Lymphocytes before and
after stimulation were also labeled with anti-TRAIL-PE (Becton
Dickinson).
Expansion and Purification of Receptor-Transduced Primary T
Cells
[0117] Receptor-transduced lymphocytes (3.times.10.sup.5) were
co-cultured with 1.5.times.10.sup.5 irradiated OP-1 cells in
RPMI-1640 with 10% FCS with or without exogenous IL-2. Cells were
pulsed weekly with irradiated target cells at an E:T ratio of 2:1.
Cells were counted by Trypan-blue dye exclusion and by flow
cytometry to confirm the presence of GFP-positive cells and the
absence of CD19-positive cells. To prepare pure populations of
CD8.sup.+ cells expressing chimeric receptors, we labeled cells
with a PE-conjugated anti-CD8 antibody (Becton Dickinson) that had
been previously dialyzed to remove preservatives and then
sterile-filtered. CD8.sup.+ GFP+ cells were isolated using a
fluorescence-activated cell sorter (MoFlo).
Cytotoxicity Assays
[0118] The cytolytic activity of transductants was measured by
assays of lactate dehydrogenase (LDH) release using the
Cytotoxicity Detection Kit (Roche, Indianapolis, Ind.) according to
the manufacturer's instructions. Briefly, 2.times.10.sup.4 target
cells were placed in 96-well V-bottom tissue culture plates
(Costar, Cambridge, Mass.) and cocultured in triplicate in
RPMI-1640 supplemented with 1% FCS, with primary lymphocytes
transduced with chimeric receptors. After 5 hours, cell-free
supernatant was harvested and immediately analyzed for LDH
activity. Percent specific cytolysis was calculated by using the
formula: (Test-effector control-low control/high control-low
control).times.100, in which "high control" is the value obtained
from supernatant of target cells exposed to 1% Triton-X-100,
"effector control" is the spontaneous LDH release value of
lymphocytes alone, "low control" is the spontaneous LDH release
value of target cells alone; background control (the value obtained
from medium alone) was subtracted from each value before the
calculation.
[0119] The anti-leukemic activity of receptor-transduced
lymphocytes was also assessed in 7-day cultures using lower E:T
ratios. For this purpose, we used bone marrow-derived mesenchymal
cells to support the viability of leukemic cells. [Nishigaki H, et
al. Prevalence and growth characteristics of malignant stem cells
in B-lineage acute lymphoblastic leukemia. Blood 89:3735-3744
(1997); Mihara K, et al. Development and functional
characterization of human bone marrow mesenchymal cells
immortalized by enforced expression of telomerase. Br J Haematol
120:846-849 (2003)] Briefly, 2.times.10.sup.4 human mesenchymal
cells immortalized by enforced expression of telomerase reverse
transcriptase were plated on a 96-well tissue culture plate
precoated with 1% gelatin. After 5 days, 1.times.10.sup.4 CD19+
target cells (in case of cell lines) or 2.times.10.sup.5 CD19+
target cells (in case of primary ALL cells) were plated on the
wells and allowed to rest for 2 hours. After extensive washing to
remove residual IL-2-containing medium, receptor-transduced primary
T cells were added to the wells at the proportion indicated in
Results. Cultures were performed in the absence of exogenous IL-2.
Plates were incubated at 37.degree. C. in 5% CO.sub.2 for 5-7 days.
Cells were harvested, passed through a 19-gauge needle to disrupt
residual mesenchymal-cell aggregates, stained with anti-CD 19-PE
antibody, and assayed by flow cytometry as previously described.
[Ito C, et al. Hyperdiploid acute lymphoblastic leukemia with 51 to
65 chromosomes: A distinct biological entity with a marked
propensity to undergo apoptosis. Blood 93:315-320 (1999);
Srivannaboon K, et al. Interleukin-4 variant (BAY 36-1677)
selectively induces apoptosis in acute lymphoblastic leukemia
cells. Blood 97:752-758 (2001)] Expression of DsRed served as a
marker of residual K562 cells. Experiments were done in
triplicate.
Results
[0120] Transduction of Primary Human T Lymphocytes with
Anti-CD19-BB-.zeta. Chimeric Receptors
[0121] In preliminary experiments, transduction of lymphocytes
stimulated with PHA (7 .mu.g/mL) and IL-2 (200 IU/mL) for 48 hours,
followed by centrifugation (at 2400.times.g) of the activated
lymphocytes with retroviral supernatant in tubes coated with
fibronectin, consistently yielded a high percentage of chimeric
receptor and GFP expression; this method was used in all subsequent
experiments. In 75 transduction experiments, 31% to 86% (median,
64%) of mononuclear cells expressed GFP. In experiments with cells
obtained from 6 donors, we tested the immunophenotype of the cells
transduced with anti-CD 19-BB-.zeta. receptors. Fourteen days after
transduction a mean (.+-.SD) of 89.6%.+-.2.3% (n=6) of GFP.sup.+
cells also expressed CD3; 66.2%.+-.17.9% of CD3.sup.+ T lymphocytes
were transduced. Among GFP.sup.+ cells, 21.1%.+-.8.8% (n=6) were
CD4.sup.+, 68.1%.+-.8.1% (n=6) were CD8.sup.+, 38.1%.+-.16.1% (n=3)
were CD28.sup.+ and 24.2%.+-.11.6% (n=3) were CD8.sup.+CD28.sup.+.
These proportions were similar to those obtained with the
anti-CD19-.zeta. receptors lacking 4-1BB. In this case,
85.4%.+-.11.0% (n=6) of GFP cells expressed CD3; 60.8%.+-.10.1% of
CD3 cells were transduced. Among GFP cells, 18.0%.+-.8.7% (n=6)
were CD4.sup.+, 66.1%.+-.11.7% (n=6) were CD8.sup.+, 41.2%.+-.12.2%
(n=3) were CD28.sup.+ and 20.6%.+-.11.3% (n=3) were CD8.sup.+. In
these experiments, median transduction efficiency was 65% (range,
31% to 86%) for anti-CD19-BB-.zeta. receptors, and 65% (range, 37%
to 83%) for anti-CD19-.zeta. receptors.
[0122] The surface expression of the chimeric receptors on
GFP.sup.+ cells was confirmed by staining with a goat anti-mouse
antibody that reacted with the scFv portion of anti-CD19.
Expression was detectable on most GFP.sup.+ cells and was not
detectable on GF{tilde over (P)} cells and vector-transduced cells.
The level of surface expression of anti-CD19-BB-.zeta. was
identical to that of the receptor lacking 4-1BB. Expression was
confirmed by Western blot analysis; under non-reducing conditions,
peripheral blood mononuclear cells transduced with the chimeric
receptors expressed them mostly as monomers, although dimers could
be detected.
Signaling Function of Anti-CD 19-BB-.zeta. Chimeric Receptors
[0123] To test the functionality of the anti-CD19-BB-.zeta.
chimeric receptor, we used the T-cell line Jurkat and the CD19+ ALL
cell line OP-1. After transduction, >95% Jurkat cells were GFP+.
Exposure of irradiated OP-1 cells to Jurkat cells transduced with
anti-CD19-BB-.zeta. triggered transcription of IL-2. Notably, in
parallel experiments with Jurkat cells transduced with the
anti-CD19-.zeta. receptor lacking 4-1BB, the level of IL-2
transcription was much lower. No IL-2 transcription was detected in
Jurkat cells transduced with the anti-CD19-truncated control
receptor lacking CD3.zeta..
[0124] To identify further changes in molecules associated with
T-cell activation, survival or cytotoxicity induced by
anti-CD19-BB-.zeta. receptors, Jurkat cells were either transduced
with these receptors or with anti-CD 19-.zeta. receptors and then
stimulated with paraformadehyde-fixed OP-1 cells. After 12 hours of
stimulation, we screened the cells' gene expression using
Affymetrix HG-U133A chips. Genes that were overexpressed by a
factor of 2 or higher in cells with anti-CD19-BB-.zeta. included
the member of the TNF family TRAIL, the TNF-receptor member OX40,
and IL-3. Overexpression of these molecules after stimulation was
validated using RT-PCR. In cells bearing the anti-CD19-.zeta.
receptor, there were no overexpressed genes with a known function
associated with T-cells. Therefore, anti-CD19-BB-.zeta. receptors
elicit transcriptional responses that are distinct from those
triggered by receptors lacking 4-1BB.
Expansion of T Cells Expressing Anti-CD19-BB-.zeta. Receptors in
the Presence of CD19 Cells
[0125] To measure the ability of anti-CD19-BB-.zeta. transduced
lymphocytes to survive and expand in vitro, we first analyzed
primary T cells (obtained from 2 donors), 7 days after
transduction. Transduction efficiency with the 3 receptors was
similar: 72% and 67% for anti-CD19-BB-.zeta., 63% and 66% for
anti-CD19-.zeta. and 67% and 68% for the truncated anti-CD19
receptor. When cocultured with irradiated OP-1 ALL cells in the
absence of exogenous IL-2, cells transduced with
anti-CD19-BB-.zeta. expanded: after only 1 week of culture,
GFP.sup.+ cells recovered were 320% and 413% of input cells. T
cells that expressed the anti-CD19-.zeta. receptor but lacked 4-1BB
signaling capacity remained viable but showed little expansion
(cell recovery: 111% and 160% of input cells, respectively),
whereas those that expressed the truncated anti-CD19 receptor
underwent apoptosis (<10% of input cells were viable after 1
week). Lymphocytes transduced with anti-CD19-BB-.zeta. continued to
expand in the presence of irradiated OP-1 cells. After 3 weeks of
culture, they had expanded by more than 16-fold, with 98% of the
cells at this point being GFP.sup.+. By contrast, cells transduced
with only anti-CD19-.zeta. survived for less than 2 weeks of
culture.
[0126] We performed the next set of experiments with T cells
(obtained from 3 donors) 14 days after transduction with
anti-CD19-BB-.zeta., anti-CD 19-.zeta. or anti-CD 19-truncated, and
expanded with high-dose IL-2 (200 IU/mL). Recovery of lymphocytes
of each donor with anti-CD19-BB-.zeta. receptors was significantly
higher than that of lymphocytes with anti-CD19-.zeta. receptors in
all 3 comparisons (P<0.005). When IL-2 was removed, exposure of
the transduced cells to irradiated OP-1 cells induced apoptosis,
irrespective of the chimeric receptor expressed. This was in
contrast to results with cells 7 days post-transduction, and in
accord with the loss of T cell functionality after prolonged
culture in IL-2 observed by others. [Brentjens R J, et al.
Eradication of systemic B-cell tumors by genetically targeted human
T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med
9:279-286 (2003); Rossig C. et al. Targeting of G(D2)-positive
tumor cells by human T lymphocytes engineered to express chimeric
T-cell receptor genes. Int J Cancer 94:228-236 (2001)] However,
low-dose IL-2 (10 IU/mL) was sufficient to maintain most
lymphocytes transduced with anti-CD19-BB-.zeta. viable after 2
weeks of culture with irradiated OP-1 cells, but did not prevent
apoptosis of cells transduced with the other receptors. Taken
together, these data indicate that 4-1BB-mediated costimulation
confers a survival advantage on lymphocytes.
Cytotoxicity Triggered by Anti-CD19-BB-.zeta. Chimeric
Receptors
[0127] Lymphocytes obtained from two donors and transduced with
anti-CD19-BB-.zeta. and anti-CD19-.zeta. exerted dose-dependent
cytotoxicity, as shown by a 5-hour LDH release assay using the OP-1
B-lineage ALL cell line as a target. Transduction efficiencies were
41% and 73% for empty vector, 40% and 67% for anti-CD19-truncated,
43% and 63% for anti-CD19-.zeta., and 46% and 72% for
anti-CD19-BB-.zeta.. No differences in cytotoxicities mediated by
the two receptors were detectable with this assay. Although no
lysis of target cells was apparent at a 1:1 ratio in the 5-hour LDH
assay, most leukemic cells were specifically killed by lymphocytes
expressing signaling chimeric receptors when the cultures were
examined at 16 hours by flow cytometry and inverted microscopy.
[0128] To better mimic the application of T-cell therapy, we
determined whether T cells expressing the chimeric receptor would
exert significant anti-leukemic activity when present at low E:T
ratios in prolonged culture. Lymphocytes from various donors were
expanded in vitro for 14 days after transduction and were mixed at
different ratios with OP-1, RS4;11, or REH B-lineage ALL cells, or
with K562 (a CD19-negative myeloid cell line that lacks HLA
antigens) transduced with CD19 or with vector alone. Co-cultures
were maintained for 7 days, and viable leukemic cells were counted
by flow cytometry. As observed in short term cultures, at a 1:1
ratio, T cells expressing signaling chimeric receptors eliminated
virtually all leukemic cells from the cultures. At a 0.1:1 ratio,
however, T cells transduced with anti-CD19-BB-.zeta. receptors were
markedly more effective than those lacking 4-1BB signaling.
Chimeric receptor-transduced T cells had no effect on cells lacking
CD19. The presence of 4-1BB in the chimeric receptor did not
increase background, non-CD19-mediated cytotoxicity, in experiments
using CEM-C7, U-937 and K-562. As in other experiments,
transduction efficiencies with the two chimeric receptors were
equivalent, and range from 62% to 73% for anti-CD19-.zeta. and from
60% to 70% for anti-CD19-BB-.zeta..
[0129] Cells present in the bone marrow microenvironment may
decrease T-cell proliferation in a mixed lymphocyte reaction.
[Bartholomew A, et al. Mesenchymal stem cells suppress lymphocyte
proliferation in vitro and prolong skin graft survival in vivo. Exp
Hematol 30:42-48 (2002); Krampera M, et al. Bone marrow mesenchymal
stem cells inhibit the response of naive and memory
antigen-specific T cells to their cognate peptide. Blood
101:3722-3729 (2003); Le Blanc K, et al. Mesenchymal stem cells
inhibit and stimulate mixed lymphocyte cultures and mitogenic
responses independently of the major histocompatibility complex.
Scand J Immunol 57:11-20 (2003)] To test whether these cells would
also affect T-cell-mediated antileukemic activity, we repeated the
experiments with OP-1 in the presence of bone marrow-derived
mesenchymal cell layers. [Mihara K, et al. Development and
functional characterization of human bone marrow mesenchymal cells
immortalized by enforced expression of telomerase. Br J Haematol
2003; 120:846-849 (2003)] T-cell cytotoxicity under these
conditions was even greater than that observed in cultures without
mesenchymal cells. Remarkably, T cells transduced with
anti-CD19-BB-.zeta. were markedly cytotoxic even at a ratio of
0.01:1 in this assay, whereas those transduced with
anti-CD19-.zeta. were not.
Effect of Receptor-Transduced T Cells on Primary Leukemic Cells
[0130] We co-cultured primary B-lineage ALL cells with bone
marrow-derived mesenchymal cells, which are essential to preserve
their viability in vitro. [Nishigaki H, et al. Prevalence and
growth characteristics of malignant stem cells in B-lineage acute
lymphoblastic leukemia. Blood 1997; 89:3735-3744 (1997); Mihara K,
et al. Development and functional characterization of human bone
marrow mesenchymal cells immortalized by enforced expression of
telomerase. Br J Haematol 120:846-849 (2003)] We tested the effect
of T cells expressing anti-CD19-BB-.zeta. on primary leukemic cells
obtained from 5 patients at the time of diagnosis; these patients
included 3 who had B-lineage ALL with 11 q23 abnormalities, a
karyotype associated with drug resistance. [Pui C H, et al.
Childhood acute lymphoblastic leukemia--Current status and future
perspectives. Lancet Oncology 2:597-607 (2001)] Mesenchymal cells
supported ALL cell survival in vitro: in cultures not exposed to
exogenous T cells, recovery of leukemic cells from the 5 patients
after 5 days of culture ranged from 100.1% to 180.7% of the input
cell number. Leukemic cells incubated at a 0.1:1 ratio with
lymphocytes expressing anti-CD19-BB-.zeta. were virtually
eliminated in all 5 cultures. Remarkable cytotoxicity was also seen
at a 0.01:1 ratio. Importantly, at this ratio, lymphocytes
expressing anti-CD19-BB-.zeta. were consistently more cytotoxic
than those expressing the anti-CD19-.zeta. receptor alone
(P<0.01 by t test for all comparisons).
Comparisons Between Chimeric Receptors Containing Signaling Domains
of 4-1BB and of CD28
[0131] We compared responses induced by anti-CD19-BB-.zeta. to
those of an equivalent receptor in which 4-1BB signaling domains
were replaced by CD28 signaling domains (FIG. 1). Expression of the
latter was similar to that of anti-CD19-BB-.zeta. and
anti-CD19-.zeta. receptors: >95% Jurkat cells were consistently
GFP+ after transduction with anti-CD19-28-.zeta. and most of these
cells had detectable receptors on the cell surface. In 6
experiments with primary lymphocytes, transduced cells ranged from
42% to 84% (median, 72%).
[0132] We tested production of IL-2 in Jurkat cells transduced with
the three receptors and stimulated with the CD19+ ALL cell line
OP-1. Production of IL-2 was the highest in cells expressing
anti-CD19-BB-.zeta. (P<0.05). Production of IL-2 was also tested
in primary lymphocytes, which were transduced with the chimeric
receptors and then expanded for 5 weeks with pulses of OP-1. The
pattern of IL-2 production was similar to that observed in Jurkat
cells. Cells expressing anti-CD19-BB-.zeta. produced higher levels
of IL-2 (P<0.01). Chimeric receptors containing the
co-stimulatory molecules induced a higher IFN-.gamma. production in
primary lymphocytes. IFN-.gamma. levels were the highest with the
anti-CD19-28-.zeta. receptor (P<0.05). Finally, we tested
surface expression of TRAIL protein in primary lymphocytes by
staining with a specific antibody. Levels of TRAIL were the highest
in cells transduced with the anti-CD19-BB-.zeta. receptor. These
results indicate that anti-CD19-BB-.zeta. receptors are
functionally distinct from those lacking co-stimulatory molecules
or containing CD28 instead of 4-1BB. Next, we compared the
cytotoxicity exerted by primary T cells transduced with
anti-CD19-BB-.zeta. receptors to those exerted by T cells bearing
receptors lacking 4-1BB. For these experiments, we transduced
primary lymphocytes from 2 donors with anti-CD19-BB-.zeta.
anti-CD19-28-.zeta., anti-CD19-.zeta. and anti-CD19-truncated, we
expanded them for 2-3 weeks with IL-2, and then purified CD8+, GFP+
cells by fluorescence activated cell sorting. Confirming our
previous results with unsorted cells, CD8+ cells expressing
anti-CD19-BB-.zeta. receptors were significantly more effective
than those with anti-CD19-.zeta. receptors, and were as effective
as those with anti-CD19-BB-.zeta. Finally, we determined the
capacity of the purified CD8 cells transduced with the various
receptors to expand in the presence of low dose (10 U/mL) IL-2.
Cells transduced with anti-CD19-BB-.zeta. receptor had a
significantly higher cell growth under these conditions than those
bearing the other receptors (P<0.001).
Discussion
[0133] Results of this study indicate that anti-CD19-BB-.zeta.
receptors could help achieve effective T-cell immunotherapy of
B-lineage ALL. Lymphocytes expressing anti-CD19-BB-.zeta. survived
and expanded better than those with equivalent receptors lacking
4-1BB. These lymphocytes also had higher anti-leukemic activity and
could kill B-lineage ALL cells from patients at E:T ratios as low
as 0.01:1, suggesting that the infusion of relatively low numbers
of transduced T cells could have a measurable anti-leukemic effect
in patients. Finally, lymphocytes transduced with
anti-CD19-BB-.zeta. were particularly effective in the presence of
bone marrow-derived mesenchymal cells which form the
microenvironment critical for B-lineage ALL cell growth, further
supporting their potential for immunotherapy.
[0134] Two recently reported studies used anti-CD19 scFv as a
component of a chimeric receptor for T-cell therapy of B-cell
malignancies. Cooper et al. Blood 101:1637-1644 (2003) reported
that T-cell clones transduced with chimeric receptors comprising
anti-CD 19 scFv and CD3.zeta. produced approximately 80% specific
lysis of B-cell leukemia and lymphoma cell lines at a 1:1 E:T ratio
in a 4-hour .sup.51Cr release assay; at this ratio, percent
specific lysis of one primary B-lineage ALL sample tested was
approximately 30%. Brentjens et al. Nat Med 279-286 (2003) reported
that T-cells bearing anti-CD19 scFv and CD3.zeta. chimeric
receptors could be greatly expanded in the presence of exogenous
IL-15 and artificial antigen-presenting cells transduced with CD19
and CD80. The authors showed that these T cells significantly
improved the survival of immunodeficient mice engrafted with the
Raji B-cell lymphoma cell line. Their results demonstrated the
requirement for co-stimulation in maximizing T-cell-mediated
anti-leukemic activity: only cells expressing the B7 ligands of
CD28 elicited effective T-cell responses. However, B-lineage ALL
cells typically do not express B7-1(CD80) and only a subset
expresses B7-2 (CD86) molecules. [Cardoso A A, et al. Pre-B acute
lymphoblastic leukemia cells may induce T-cell anergy to
alloantigen. Blood 88:41-48 (1996)]
[0135] 4-1BB, a tumor necrosis factor-receptor family member, is a
co-stimulatory receptor that can act independently from CD28 to
prevent activation-induced death of activated T cells. [Kim Y J, et
al. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell
responses. Eur J Immunol 28:881-890 (1998); Hurtado J C, et al.
Signals through 4-1BB are costimulatory to previously activated
splenic T cells and inhibit activation-induced cell death. J
Immunol 158:2600-2609 (1997); DeBenedette M A, et al. Costimulation
of CD28-T lymphocytes by 4-1BB ligand. J Immunol 1997; 158:551-559
(1997); Bukczynski J, et al. Costimulation of human CD28-T cells by
4-1BB ligand. Eur J Immunol 33:446-454 (2003)] In our study, we
found that chimeric receptors containing 4-1BB can elicit vigorous
signals in the absence of CD28-mediated co-stimulation.
Cytotoxicity against CD19.sup.+ cells mediated by these receptors
was as good as that mediated by CD28-containing receptors and was
clearly superior to that induced by receptors lacking
co-stimulatory molecules. It is known that, in contrast to CD28,
4-1BB stimulation results in a much larger proliferation of
CD8.sup.+ cells than CD4+ cells. [Shuford W W, et al. 4-1BB
costimulatory signals preferentially induce CD8.sup.+ T cell
proliferation and lead to the amplification in vivo of cytotoxic T
cell responses. J Exp Med 1997; 186:47-55 (1997)] We found that T
cells expressing the anti-CD19-BB-.zeta. receptor produced more
IL-2 upon stimulation, and that CD8.sup.+ cells expanded in the
presence of low-dose IL-2 more vigorously than those expressing
receptors lacking 4-1BB domains, including those containing CD28.
Therefore, the presence of 4-1BB in the chimeric receptors may
support more durable T cell responses than those induced by other
receptors.
[0136] Experimental evidence indicates that harnessing 4-1BB
signaling could have useful application in antitumor therapy.
Melero et al. Nat Med 3:682-685 (1997) found that antibodies to
4-1BB significantly improved long-lasting remission and survival
rates in mice inoculated with the immunogenic P815 mastocytoma cell
line. Moreover, immunogenic murine tumor cells made to express
4-1BB ligand were readily rejected and induced long term immunity.
[Melero I, et al. Chen L. Amplification of tumor immunity by gene
transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28
co-stimulatory pathway. Eur J Immunol 28:1116-1121 (1998)] Dramatic
results were also observed in vaccination experiments using other
tumor cell lines expressing 4-1BB ligands. [Ye Z, et al. Gene
therapy for cancer using single-chain Fv fragments specific for
4-1BB. Nat Med 8:343-348 (2002); Mogi S, et al. Tumour rejection by
gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell
carcinoma and the requirements of co-stimulatory molecules on
tumour and host cells. Immunology 101:541-547 (2000); Yoshida H, et
al. A novel adenovirus expressing human 4-1BB ligand enhances
antitumor immunity. Cancer Immunol Immunother 52:97-106 (2003)] Of
note, experiments with the poorly immunogenic Ag104A fibrosarcoma
cell line provided some evidence that 4-1BB could be superior to
CD28 in eliciting anti-tumor responses: 80% of mice showed tumor
regression with 4-1BB stimulation and 50% of mice with widespread
metastasis were cured, [Melero I, Shuford W W, Newby S A, et al.
Monoclonal antibodies against the 4-1BB T-cell activation molecule
eradicate established tumors. Nat Med 3:682-685 (1997)] whereas
CD28 costimulation was not effective alone and required
simultaneous CD2 stimulation. [Li Y, et al. Costimulation by CD48
and B7-1 induces immunity against poorly immunogenic tumors. J Exp
Med 1996; 183:639-644 (1996)] These data, together with our
results, indicate that the addition of 4-1BB to the chimeric
receptor should significantly increase the probability that
transduced T-cells will survive and continue to proliferate when
the receptor is engaged in vivo. We think it noteworthy that T
cells with chimeric receptors containing 4-1BB expressed the
highest levels of TRAIL upon stimulation, given the known
tumoricidal activity of this molecule. [Schmaltz C, et al. T cells
require TRAIL for optimal graft-versus-tumor activity. Nat Med
8:1433-1437 (2002)]
[0137] Clinical precedents, such as administration of T-cell clones
that target CMV epitopes [Walter E A, et al. Reconstitution of
cellular immunity against cytomegalovirus in recipients of
allogeneic bone marrow by transfer of T-cell clones from the donor.
N Engl J. Med. 333:1038-1044 (1995)] or EBV-specific antigens,
[Rooney C M, et al. Use of gene-modified virus-specific T
lymphocytes to control Epstein-Barr-virus-related
lymphoproliferation. Lancet 345:9-13 (1995)] attest to the clinical
feasibility of adoptive T-cell therapy. Transfer of chimeric
receptor-modified T cells has the added advantage of permitting
immediate generation of tumor-specific T-cell immunity.
Subsequently, therapeutic quantities of antigen-specific T cells
can be generated quite rapidly by exposure to target cells and/or
artificial antigen-presenting cells, in the presence of ligands of
co-stimulatory molecules and/or exogenous cytokines such as IL-2,
IL-7, and IL-15. [Geiger T L, Jyothi M D. Development and
application of receptor-modified T lymphocytes for adoptive
immunotherapy. Transfus Med Rev 15:21-34 (2001); Schumacher T N.
T-cell-receptor gene therapy. Nat Rev Immunol. 2:512-519 (2002);
Sadelain M, et al. Targeting tumours with genetically enhanced T
lymphocytes. Nat Rev Cancer 3:35-45 (2003); Brentjens R J, et al.
Eradication of systemic B-cell tumors by genetically targeted human
T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med
9:279-286 (2003)] A specific risk of the strategy proposed here
relates to the transforming potential of the retrovirus used to
transduce chimeric receptors. [Baum C, Dullmann J, Li Z, et al.
Side effects of retroviral gene transfer into hematopoietic stem
cells. Blood 101:2099-2114 (2003)] We therefore envisage the
coexpression of suicide genes as a safety measure for clinical
studies. [Marktel S, et al. Immunologic potential of donor
lymphocytes expressing a suicide gene for early immune
reconstitution after hematopoietic T-cell-depleted stem cell
transplantation. Blood 101:1290-1298 (2003)] This approach would
also ensure that the elimination of normal CD 19.sup.+ B-lineage
cells is temporary and should therefore have limited clinical
consequences.
[0138] In view of the limited effectiveness and the high risk of
the currently available treatment options for
chemotherapy-refractory B-lineage ALL and other B cell
malignancies, the results of our study provide compelling
justification for clinical trials using T cells expressing
anti-CD19-BB-.zeta. receptors. Donor-derived T cells endowed with
chimeric receptors could replace infusion of non-specific
lymphocytes post-transplant. To reduce the risk of GvHD mediated by
endogenous T-cell receptors, it may be beneficial to use T cells
with restricted endogenous specificity, for example,
Epstein-Barr-virus-specific cytotoxic T-lymphocyte lines. [Rossig
C, et al. Epstein-Barr virus-specific human T lymphocytes
expressing antitumor chimeric T-cell receptors: potential for
improved immunotherapy. Blood. 99:2009-2016 (2002)] Therefore, it
would be important to test the effects of adding 4-1BB to chimeric
receptors transduced in these lines. The reinfusion of autologous T
cells collected during clinical remission could also be considered
in patients with persistent minimal residual disease. In our
experiments, T cells expressing anti-CD19-BB-.zeta. receptors
completely eliminated ALL cells at E:T ratios higher than 1:1, and
autologous B lymphocytes became undetectable shortly after
transduction of anti-CD 19-BB-.zeta., suggesting that the potential
leukemic cell contamination in the infused products should be
greatly reduced or abrogated by the procedure.
9.2 Example 2
[0139] T lymphocytes transduced with anti-CD19 chimeric receptors
have remarkable anti-ALL capacity in vitro and in vivo, suggesting
the clinical testing of receptor-modified autologous T cells in
patients with persistent minimal residual disease. However, the use
of allogeneic receptor-modified T lymphocytes after hematopoietic
cell transplantation (HCT) might carry the risk of severe
graft-versus-host disease (GvHD). In this setting, the use of
CD3-negative natural killer (NK) cells is attractive because they
should not cause GvHD.
[0140] Spontaneous cytotoxicity of NK cells against ALL is weak, if
measurable at all. To test whether anti-CD 19 chimeric receptors
could enhance it, we developed methods to specifically expand human
primary NK cells and induce high levels of receptor expression.
Specific NK cell expansion has been problematic to achieve with
established methods which favor CD3+ T cell expansion. Even after
T-cell depletion, residual T cells typically become prominent after
stimulation.
[0141] We overcame this obstacle by generating a
genetically-modified K562 myeloid leukemia cell line that expresses
membrane-bound interleukin-15 (IL-15) and 4-1BB ligand (CD137L)
(K562-mb15-137L). The K562-mb15-137 cell line was generated by
retrovirally transducing K562 cells with a chimeric protein
construct consisting of human IL-15 mature peptide fused to the
signal peptide and transmembrane domain of human CD8alpha, as well
as GFP. Transduced cells were single cell-cloned by limiting
dilution and a clone with the highest expression of GFP and
membrane-bound (surface) IL-15 was selected. Then, the clone was
transduced with human CD137L.
[0142] Peripheral blood mononuclear cells from 8 donors were
cultured with K562-mb15-137L in the presence of 10 IU/mL IL-2.
After 1 week of culture with K562-mb15-137L, NK cells expanded by
16.3.+-.5.9 fold, whereas T cells did not expand. The stimulatory
effect of K562-mb15-137L was much higher than that of K562 cells
transduced with control vectors, K562 expressing membrane-bound
IL-15 or CD137L alone, or K562 expressing wild-type IL-15 instead
of membrane-bound IL-15.
[0143] NK cells expanded with K562-mb15-137L were transduced with a
retroviral vector and the anti-CD19-BB-.zeta. chimeric receptor. In
27 experiments, mean transduction efficiency (.+-.SD) after 7-14
days was 67.5%.+-.16.7%. Seven to fourteen days after transduction,
92.3% (range 84.7%-99.4%) of cells were CD3-CD56+ NK cells;
expression of receptors on the cell surface was high. NK cells
expressing anti-CD19-BB-.zeta. had powerful cytotoxicity against
NK-resistant B-lineage ALL cells. NK cells transduced with
anti-CD19-BB-.zeta. had consistently higher cytotoxicity than those
transduced with receptors lacking 4-1BB.
Transduction of NK Cells with Chimeric Receptors
[0144] Peripheral blood mononuclear cells were stimulated with the
K562-mb15-137L cells prior to their exposure to retroviral vectors
containing anti-CD19 receptor constructs and GFP. In 10
experiments, median percent of NK cells was 98.4% (93.7-99.4%) 7-11
days after transduction; 77.4% (55.2-90.0%) of these cells were
GFP+. We observed high levels of surface expression of the
anti-CD19 chimeric receptors.
[0145] NK activity against the CD19-negative cells K562 and U937
was not affected by the expression of anti-CD19 receptors. The
receptors, however, markedly increased NK activity against CD
19.sup.+ ALL cells. The following summarizes results obtained with
NK cells from 2 donors. At an E:T ratio of 1:1, NK cells from donor
1 lacked cytotoxicity against CD19.sup.+ RS4;11 cells and exerted
.about.50% cytoxicity against CD19.sup.+ 697 cells after 24 hours.
NK cells from donor 2 had no cytotoxicity against RS4;11 or 697
cells. Expression of the anti-CD19-CD3.epsilon. receptor overcame
NK resistance. NK cells from donor 1 became cytotoxic to RS4;11
cells and those from donor 2 become cytotoxic to both RS;11 and 697
cells. Moreover, when control cells had some cytotoxicity, this was
significantly augmented by expression of signaling anti-CD 19
receptor.
[0146] Subsequently, we found that addition of the co-stimulatory
CD28 or 4-1BB to the anti-CD 19 receptor markedly enhanced NK
cytotoxicity against NK-resistant ALL cells (FIG. 2). For example,
after 24 hours of culture at 1:1 E:T ratio, the cytotoxicity
mediated by the anti-CD19-BB-.zeta. receptor against the
NK-resistant CD19.sup.+ ALL cell lines 380, 697, KOPN57bi and OP1
ranged from 86.5% to 99.1%. Therefore, the inclusion of
co-stimulatory molecules enhances not only the cytoxicity of T
lymphocytes but also that of NK cells.
9.3 Example 3
Artificial Antigen Producing Cells (APCs) Pave The Way For Clinical
Application By Potent Primary In Vitro Induction
Materials And Methods
Cells
[0147] The CD 19 human B-lineage ALL cell lines RS4;11, OP-1, 380,
697, and KOPN57bi; the T-cell line GEM-C7; and the myeloid cell
lines K562 and U-937 were available in our laboratory. Cells were
maintained in RPMI-1640 (Gibco, Grand Island, N.Y.) supplemented
with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, Md.)
and antibiotics.
[0148] Primary leukemia cells were obtained with appropriate
informed consent and Institutional Review Board (M) approval from
nine patients with B-lineage ALL; from four of these patients, we
also studied (with IRB approval) cryopreserved peripheral blood
samples obtained during clinical remission. An unequivocal
diagnosis of B-lineage ALL was established by morphologic,
cytochemical, and immunophenotypic criteria; in each case, more
than 95% of the cells were positive for CD19. Peripheral blood was
obtained from eight healthy adult donors. Mononuclear cells
collected from the samples by centrifugation on a Lymphoprep
density step (Nycomed, Oslo, Norway) were washed twice in
phosphate-buffered saline (PBS) and once in AIM-V medium
(Gibco).
Plasmids and Retrovirus Production
[0149] The anti-CD 19-.zeta., anti-CD19-BB-i and
anti-CD19-truncated (control) plasmids are described in Imai, C, et
al., Leukemia 18:676-684 (2004). The pMSCV-IRES-GFP, pEQPAM3(-E),
and pRDF constructs were obtained from the St. Jude Vector
Development and Production Shared Resource. The intracellular
domains of human DAP 10, 4-1BB ligand and interleukin-15 (IL-15)
with long signal peptide were subcloned by polymerase chain
reaction (PCR) with a human spleen cDNA library (from Dr. G. Neale,
St. Jude Children's Research Hospital) used as a template. An
antiCD 19-DAP 10 plasmid was constructed by replacing the
intracellular domain of anti-CD 19-.zeta. with that of DAP 10,
using the SOE-PCR (splicing by overlapping extension by PCR)
method. The signal peptide of CD8 cc, the mature peptide of IL-15
and the transmembrane domain of CDB.alpha. were assembled by
SOE-PCR to encode a "membrane-bound" form of IL-15. The resulting
expression cassettes were subcloned into EcoRI and XhoI sites of
MSCV-IRES-GFP.
[0150] The RD114-pseudotyped retrovirus was generated as described
in Imai, C, et al., Leukemia 18:676-684 (2004). We used calcium
phosphate DNA precipitation to transfect 293T cells with
anti-CD19-.zeta., anti-CD19-DAP10, anti-CD19-BB-.zeta., or anti-CD
19-truncated; pEQ-PAM3(-E); and pRDF. Conditioned medium containing
retrovirus was harvested at 48 hours and 72 hours after
transfection, immediately frozen in dry ice, and stored at
-80.degree. C. until use.
Development of K562 Derivatives, Expansion of NK Cells and Gene
Transduction
[0151] K562 cells were transduced with the construct encoding the
"membrane-bound" form of IL-15. Cells were cloned by limiting
dilution, and a single-cell clone with high expression of GFP and
of surface IL-15 ("K562-mb15") was expanded. This clone was
subsequently transduced with human 4-1BB ligand and designated as
"K562-mb15-41BBL". K562 cells expressing wild-type IL-15
("K562-wt15") or 4-IBBL ("K562-41BBL") were produced by a similar
procedure. Peripheral blood mononuclear cells (1.5.times.106) were
incubated in a 24-well tissue culture plate with or without 106
K562-derivative stimulator cells in the presence of 10 N/mL human
IL-2 (National Cancer Institute BRB Preclinical Repository,
Rockville, Md.) in RPMI-1640 and 10% FCS.
[0152] Mononuclear cells stimulated with K562-mb15-41BBL were
transduced with retroviruses, as previously described for T cells
[Melero I, et al., NK1.1 cells express 4-iBB (CDw137) costimulatory
molecule and are required for tumor immunity elicited by anti-4-1BB
monoclonal antibodies. Cell Immunol 190:167-172 (1998)]. Briefly,
14-mL polypropylene centrifuge tubes (Falcon) were coated with
human fibronectin (100 .mu.g/mL; Sigma, St. Louis, Mo.) or
RetroNectin (50 .mu.g/mL; TaKaRa, Otsu, Japan). Prestimulated cells
(2.times.10.sup.5) were resuspended in the tubes in 2-3 mL of
virus-conditioned medium with polybrene (4 .mu.g/mL; Sigma) and
centrifuged at 2400.times.g for 2 hours (centrifugation was omitted
when RetroNectin was used). The multiplicity of infection (4 to 6)
was identical in each experiment comparing the activity of
different chimeric receptors. After centrifugation, cells were left
undisturbed for 24 hours in a humidified incubator at 37.degree.
C., 5% CO.sub.2. The transduction procedure was repeated on two
successive days. After a second transduction, the cells were
re-stimulated with K562-mb 15-4 1BBL in the presence of 10 IU/mL of
IL-2. Cells were maintained in RPMI-1640, 10% FCS, and 10 IU/mL
IL-2.
Detection of Chimeric Receptor Expression and Immunophenotyping
[0153] Transduced NK cells were stained with goat anti-mouse
(Fab).sup.2 polyclonal antibody conjugated with biotin (Jackson
Immunoresearch, West Grove, Pa.) followed by streptavidin
conjugated to peridinin chlorophyll protein (PerCP; Becton
Dickinson, San Jose, Calif.). For Western blotting, cells were
lysed in RIPA buffer (PBS, 1% Triton-X100, 0.5% sodium
deoxycholate, 0.1% SDS) containing 3 .mu.g/mL of pepstatin, 3
.mu.g/mL of leupeptin, 1 mM of PMSF, 2 mM of EDTA, and 5 .mu.g/mL
of aprotinin. Centrifuged lysate supernatants were boiled with an
equal volume of loading buffer with or without 0.1 M DTT, and then
separated by SDS PAGE on a precast 10-20% gradient acrylamide gel
(BioRad, Hercules, Calif.). The proteins were transferred to a PVDF
membrane, which was incubated with primary mouse anti-human
CD3.zeta. monoclonal antibody (clone 8D3; Pharmingen). Membranes
were then washed, incubated with a goat anti-mouse IgG horseradish
peroxidase-conjugated second antibody, and developed by using the
ECP kit (Pharmacia, Piscataway, N.J.).
[0154] The following antibodies were used for immunophenotypic
characterization of expanded and transduced cells: anti-CD3
conjugated to fluorescein isothiocyanate (FITC), to peridinin
chlorophyll protein (PerCP) or to energy-coupled dye (ECD); anti-CD
10 conjugated to phycoerythrin (PE); anti-CD19 PE; anti-CD22 PE;
anti-CD56 FITC, PE or allophycocyanin (AFC); anti-CD 16 CyChrome
(antibodies from Becton Dickinson; Pharmingen, San Diego; or
Beckman-Coulter, Miami, Fla.); and anti-CD25 PE (Dako, Carpinteria,
Calif.). Surface expression of KIR and NK activation molecules was
determined with specific antibodies conjugated to FIX or PE (from
Beckman-Coulter or Becton-Dickinson), as previously described
[Brentjens R J, Latouche J B, Santos E, et al. Eradication of
systemic B-cell tumors by genetically targeted human T lymphocytes
co-stimulated by CD80 and interleukin-15. Nat Med 9:279-286
(2003)]. Antibody staining was detected with a FACScan or a LSR II
flow cytomete (Becton Dickinson).
Cytotoxicity Assays and Cytokine Production
[0155] Target cells (1.5.times.105) were placed in 96-well
U-bottomed tissue culture plates (Costar, Cambridge, Na) and
incubated with primary NK cells transduced with chimeric receptors
at various effector:target (E:T) ratios in RPMI-1640 supplemented
with 10% FCS; NK cells were cultured with 1000 U/mL IL-2 for 48
hours before the assay. Cultures were performed in the absence of
exogenous IL-2. After 4 hours and 24 hours, cells were harvested,
labeled with CD10 PE or CD22 PE and CD56 FITC, and assayed by flow
cytometry as previously described. The numbers of target cells
recovered from cultures without NK cells were used as a
reference.
[0156] For cytokine production, primary NK cells (2.times.10.sup.5
in 200 .mu.l) expressing chimeric receptors were stimulated with
various target cells at a 1:1 ratio for 24 hours. The levels of
IFN-.gamma. and GM-CSF in cell-free culture supernatants were
determined with a Bio-Plex assay (BioRad).
Statistical Analysis
[0157] A test of equality of mean NK expansion with various stimuli
was performed using analysis of variance for a randomized complete
block design with each donor considered a random block. Tukey's
honest significant difference procedure was used to compute
simultaneous confidence intervals for each pairwise comparison of
the differences of treatment means. Differences in cytotoxicities
and cytokine production among NK cells bearing different chimeric
receptors were analyzed by the paired Student's t test.
Results
[0158] Culture Conditions that Favor the Expansion of Primary NK
Cells
[0159] To transduce chimeric receptors into primary NK cells, we
searched for stimuli that would induce specific NK cell
proliferation. In preliminary experiments, peripheral blood
mononuclear cells of CD3.sup.+ T lymphocytes were depleted and the
remaining cells were stimulated with IL-2 (1000 U/mL) or IL-15 (10
ng/mL). Under these culture conditions there was no expansion of NK
cells, which in fact progressively declined in numbers. With PHA (7
mg/mL) and IL-2 (1000 U/mL) as stimuli, we observed a 2- to 5-fold
expansion of CD56.sup.+ CD3.sup.- NK cells after 1 week of culture.
However, despite the low proportion of contaminating CD3.sup.+
cells (<2% in two experiments) at the beginning of the cultures,
these cells expanded more than NK cells (>30-fold expansion),
and after 1 week of culture represented approximately 35% of the
cell population.
[0160] NK cells can be stimulated by contact with the human
leukemia cell line K562, which lacks HLA-antigen expression,
[Robertson M J, Cameron C, Lazo S, Cochran K J, Voss S D, Ritz J.
Costimulation of human natural killer cell proliferation: role of
accessory cytokines and cell contact-dependent signals. Nat Immun
15:213-226 (1996)] and genetically modified K562 cells have been
used to stimulate cytotoxic T lymphocytes [Maus M V, Thomas A K,
Leonard D G, et al. Ex vivo expansion of polyclonal and
antigen-specific cytotoxic T lymphocytes by artificial APCs
expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat
Biotechnol 20:143-148 (2002)]. We tested whether the NK-stimulatory
capacity of K562 cells could be increased through enforced
expression of additional NK-stimulatory molecules, using two
molecules that are not expressed by K562 cells and are known to
stimulate NK cells. One molecule, the ligand for 4-1BB (4-1BBL),
triggers activation signals after binding to 4-1BB (CD 137), a
signaling molecule expressed on the surface of NK cells [Melero I,
Johnston N, Shufford W W, Mittler R S, Chen L. NK1.I cells express
4-IBB (CDw137) costimulatory molecule and are required for tumor
immunity elicited by anti-4-IBB monoclonal antibodies. Cell Immunol
190:167-172 (1998)]. The other molecule, IL-15, is a cytokine known
to promote NK-cell development and the survival of mature NK cells
[Carson W E, Fehniger T A, Haldar S, et al. A potential role for
interleukin-15 in the regulation of human natural killer cell
survival J Clin Invest. 99:937-943 (1997); Cooper M A, Bush J E,
Fehniger T A, et al. In vivo evidence for a dependence on
interleukin 15 for survival of natural killer cells. Blood
100:3633-3638 (2002); Fehniger T A, Caligiuri M A. Ontogeny and
expansion of human natural killer cells: clinical implications. Int
Rev Immunol 20:503-534 (2001); Wu J, Lanier LL. Natural killer
cells and cancer. Adv Cancer Res 90:127-56.:127-156 (2003)]. Since
IL-15 has greater biological activity when presented to NK cells
bound to IL-15Ra on the cell membrane of stimulatory cells, rather
than in its soluble form, we made a construct containing the human
IL-15 gene fused to the gene encoding the human CD8.alpha.,
transmembrane domain, and used it to transduce K562 cells.
Expression of IL-15 on the surface of K562 cells was more than five
times higher with the IL-15-CD8.alpha. construct than with
wild-type IL-15.
[0161] To test whether the modified K562 cells expressing both
4-11313L and IL-15 (K562 mb15-41BBL cells) promote NK cell
expansion, we cultured peripheral blood mononuclear cells from
seven donors in the presence of low-dose (10 U/mL) IL-2 as well as
irradiated K562 cells transduced with 4-1BBL and/or IL-15, or with
an empty control vector. Expression of either 4-1BBL or IL-15 by
K562 cells improved the stimulation of NK-stimulatory capacity of
K562 in some cases but not overall, whereas simultaneous expression
of both molecules led to a consistent and striking amplification of
NK cells (median recovery of CD56.sup.+ CD3.sup.- cells at 1 week
of culture, 2030% of input cells [range, 1020%-2520%] compared with
a median recovery of 250% [range, 150%-640%] for K562 cells lacking
4-1BBL and IL-15; P<0.0001). In 24 experiments with cells from 8
donors, NK-cell expansion after 3 weeks of culture with K562 cells
expressing both stimulatory molecules ranged from 309-fold to
12,409 fold (median, 1089-fold). Neither the modified nor
unmodified K562 cells caused an expansion of T lymphocytes. Among
expanded CD56.sup.+ CD3.sup.- NK cells, expression of CD56 was
higher than that of unstimulated cells; expression of CD16 was
similar to that seen on unstimulated NK cells (median CD16+ NK
cells in 7 donors: 89% before expansion and 84% after expansion).
We also compared the expression of KIR molecules on the expanded NK
cells with that on NK cells before culture, using the monoclonal
antibodies CD158a (against KIR 2DL1), CD158b (2DL2), NKBI (3DL1)
and NKAT2 (2DL3). The prevalence of NK subsets expressing these
molecules after expansion resembled that of their counterparts
before culture, although the level of expression of KIR molecules
was higher after culture. Similar results were obtained for the
inhibitory receptor CD94, while expression of the activating
receptors NKp30 and NKp44 became detectable on most cells after
culture. In sum, the immunophenotype of expanded NK cells
reiterated that of activated NK cells, indicating that contact with
K562-mb1541BBL cells had stimulated expansion of all subsets of NK
cells.
Transduction of NK Cells with Chimeric Receptors
[0162] Before transducing peripheral blood mononuclear cells with
retroviral vectors containing chimeric receptor constructs and GFP,
we stimulated them with K562-mb15-41BBL cells. In 27 experiments,
the median percentage of NK cells that were GFP.sup.+ at 7-11 days
after transduction was 69% (43%-93%). Chimeric receptors were
expressed at high levels on the surface of NK cells and, by Western
blotting, were in both monomeric and dimeric configurations.
[0163] To identify the specific signals required to stimulate NK
cells with chimeric receptors, and overcome inhibitory signals
mediated by KIR molecules and other NK inhibitory receptors that
bind to HLA class 1 molecules, we first compared two types of
chimeric receptors containing different signaling domains:
CD3.zeta., a signal-transducing molecule containing three
immunoreceptor tyrosine-based activation motifs (ITAMs) and linked
to several activating receptors expressed on the surface of NK
cells [Farag S S, Fehniger T A, Ruggeri L, Velardi A, Caligiuri M
A. Natural killer cell receptors: new biology and insights into the
graft-versus-leukemia effect. Blood 100:1935-1947 (2002); Moretta
L, Moretta A. Unravelling natural killer cell function: triggering
and inhibitory human NK receptors. EMBO J. 23:255-259 (2004)], and
DAP 10, a signal transducing molecule with no ITAMs linked to the
activating receptor NKG2D and previously shown to trigger NK
cytotoxicity [Farag S S, Fehniger T A, Ruggeri L, Velardi A,
Caligiuri M A. Natural killer cell receptors: new biology and
insights into the graft-versus-leukemia effect. Blood 100:1935-1947
(2002); Moretta L, Moretta A. Unravelling natural killer cell
function: triggering and inhibitory human NK receptors. EMBO J.
23:255-259 (2004); Billadeau D D, Upshaw J L, Schoon R A, Dick C J,
Leibson P J. NKG2D-DAPIO triggers human NK cell-mediated killing
via a Syk-independent regulatory pathway. Nat ImmuNo. 4:557-564
(2003)]. As a control, we used NK cells transduced with a vector
containing an antiCD19 receptor but no signaling molecules or
containing GFP alone.
[0164] NK cells were challenged with the CD19.sup.+ leukemic cell
lines 380, 697 and RS4;11, all of which express high levels of
HLA-class 1 molecules by antibody staining By genotyping, RS4;11 is
Cw4/Cw3, Bw4 and A3; 380 is Cw4/Cw4, Bw4; and 697 is Cw3/Cw3.
Hence, these cell lines were fully capable of inhibiting NK cell
cytotoxicity via binding to NK inhibitory receptors.
[0165] Expression of receptors without signaling molecules did not
increase NK-mediated cytotoxicity over that exerted by NK cells
transduced with the vector containing only GFP. By contrast,
expression of anti-CD 19-.zeta. receptors markedly enhanced NK
cytotoxicity in all experiments, regardless of the intrinsic
ability of donor NK cells to kill leukemic targets. For example,
380 cells were highly resistant to NK cells from donors 2 and 3,
but were killed when these donor cells expressed anti-CD 19-.zeta.
receptors. Similar observations were made for RS4; 11 cells and the
NK cells of donor 1 and for 697 cells and NK cells of donor 2.
Moreover, the anti-CD 19-.zeta. receptors led to improved killing
of target cells even when natural cytotoxicity was present. In all
experiments, the cytotoxicity triggered by the anti-CD19-.zeta.
receptor was enhanced over that achieved by replacing CD3.zeta.
with DAP 10 (P<0.001).
4-1BB-Mediated Costimulatory Signals Enhance NK Cytotoxicity
[0166] Previous studies have shown that the addition of
costimulatory molecules to chimeric receptors enhances the
proliferation and cytotoxicity of T lymphocytes [Imai C, Mihara K,
Andreansky M, Nicholson I C, Pui C H, Campana D. Chimeric receptors
with 4-1BB signaling capacity provoke potent cytotoxicity against
acute lymphoblastic leukemia. Leukemia 18:676-684 (2004)]. Of the
two best known costimulatory molecules in T lymphocytes, CD28 and
4-1BB, only 4-1BB is expressed by NK cells [Melero I, Johnston J V,
Shufford W W, Mittler R S, Chen L. NKLI cells express 4-1BB
(CDw137) costimulatory molecule and are required for tumor immunity
elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998;
190:167-172 (1998); Lang S, Vujanovic N L, Wollenberg B, Whiteside
T L. Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human
NK cells. Eur J Immunol 28:780-786 (1998); Goodier M R, Londei M.
CD28 is not directly involved in the response of human CD3CD56+
natural killer cells to lipopolysaccharide: a role for T cells.
Immunology 111:384-390 (2004)]. We determined whether the addition
of 4-1BB to the anti-CD 19-.zeta. receptor would enhance NK
cytotoxicity. In a 4 hour-cytotoxicity assay, cells expressing the
41BB-augmented receptor showed a markedly better ability to kill
CD19.sup.+ cells than did cells lacking this modification. The
superiority of NK cells bearing the anti-CD19-BB-.zeta. receptor
was also evident in 24-hour assays with NK cells from different
donors cultured at a 1:1 ratio with the leukemia cell lines 697,
KOPN57bi and OP-1.
[0167] Next, we determined whether the antileukemic activity of NK
cells expressing anti-CD19-BB-.zeta. receptors extended to primary
leukemic samples. In five samples from children with different
molecular species of ALL, NK cells expressing the 4-1BB receptors
exerted strong cytotoxicity that was evident even at low E:T ratios
(e.g., <1:1; FIG. 7) and uniformly exceeded the activity of NK
cells expressing signaling receptors that lacked 4-1BB. Even when
donor NK cells had natural cytotoxicity against ALL cells and
CD3.zeta. receptor did not improve it, addition of 4-1BB to the
receptor significantly enhanced cytotoxicity. Consistent with their
increased cytotoxicity, NK cells expressing anti-CD19-BB-.zeta.
mediated more vigorous activation signals. Forty-six percent of NK
cells bearing this receptor expressed the IL2 receptor a chain CD25
after 24 hours of coculture with CD19.sup.+ ALL cells, compared
with only 17% of cells expressing the anti-CD19-.zeta. receptor and
<1% for cells expressing receptors that lacked stimulatory
capacity. Moreover, anti-CD19-BB-.zeta. receptors induced a much
higher production of IFN-g and GM-CSF upon contact with CD19.sup.+
cells than did receptors without 41BB.
[0168] We asked whether the expression of signaling chimeric
receptors would affect spontaneous NK activity against NK-sensitive
cell lines not expressing CD19. Spontaneous cytotoxicity of NK
cells from three donors against the CD19.sup.- leukemia cell lines
K562, U937 and CEM-C7 was not diminished by expression of chimeric
receptors, with or without 4-1BB.
Anti-CD19 Chimeric Receptors Induce NK Cytotoxicity Against
Autologous Leukemic Cells
[0169] To determine whether the NK cell expansion and transduction
system that we developed would be applicable to clinical samples,
we studied peripheral blood samples that had been obtained (and
cryopreserved) from four patients with childhood B-lineage ALL in
clinical remission, 25-56 weeks from diagnosis. NK cell expansion
occur in all four samples: recovery of after one week of culture
with K562-mb15-41BBL cells, recovery of CD56.sup.+ CD3.sup.- NK
cells ranged from 1350% to 3680% of the input.
[0170] After transduction with chimeric receptors, we tested the
cytotoxicity of the NK cells against autologous leukemic
lymphoblasts obtained at diagnosis. Expression of
anti-CD19-BB-.zeta. receptors overcame NK cell resistance of
autologous cells; NK cells expressing the receptors exerted
cytotoxicity which was as powerful as that observed with allogeneic
targets.
Discussion
[0171] In this study, we demonstrated that the resistance of cancer
cells to NK cell activity can be overcome by chimeric receptors
expressed on primary NK cells. The stimulatory signals triggered by
the receptors upon contact with target cells predominated over
inhibitory signals and induced powerful cytotoxicity against
NK-resistant leukemic cell lines and primary leukemic cells. We
found that the type of stimulatory signal delivered by the chimeric
receptor was a key factor in inducing cytotoxicity. Although DAP 10
signaling can elicit NK cytotoxicity, chimeric receptors containing
this molecule in our study induced weaker NK cell activity than
that generated by CD3.zeta.-containing receptors, despite identical
levels of surface expression. We also found that addition of the
costimulatory molecule 4-1BB to the chimeric receptors markedly
augmented cytotoxicity, and that receptors containing both
CD3.zeta. and 4-1BB triggered a much more robust NK cell activation
and cytokine production than did those containing only
CD3.zeta..
[0172] The important contribution of 4-1BB signals agrees with
findings that anti-4-I BB antibodies activate murine NK cells [Pan
P Y, et al., Regulation of dendritic cell function by NK cells:
mechanisms underlying the synergism in the combination therapy of
IL-12 and 4-1BB activation. J Immunol 172:4779-4789 (2004)], and
enhance their anti-tumor activity. Leukemic lymphoid cells usually
do not express 4-1BB ligand: only 2 of 284 diagnostic B-lineage ALL
samples studied by gene arrays at our institution expressed 4-I BB
ligand transcripts [Yeoh E J, et al., Classification, subtype
discovery, and prediction of outcome in pediatric acute
lymphoblastic leukemia by gene expression profiling. Cancer Cell
1:133-143 (2002)]. Hence, 4-1BB signals can be delivered to NK
cells only if the molecule is incorporated into the receptor.
[0173] Efficient and stable transduction of primary NK cells is
notoriously difficult, prompting us to devise a new gene
transduction method for the present study. Most investigators have
demonstrated efficient gene transfer only in continuously growing
NK cell lines [Roberts M R, et al., Antigen-specific cytolysis by
neutrophils and NK cells expressing chimeric immune receptors
bearing zeta or gamma signaling domains. J. Immunol. 161:375-384
(1998); Nagashima S, et al., Stable transduction of the
interleukin-2 gene into human natural killer cell lines and their
phenotypic and functional characterization in vitro and in vivo.
Blood 91:3850-3861 (1998)] or reported methods yielding only
transient gene expression [Billadeau D D, et al., NKG2D-DAP 10
triggers human NK cell-mediated killing via a Syk-independent
regulatory pathway. Nat ImmuNo. 4:557-564 (2003); Trompeter H I, et
al., Rapid and highly efficient gene transfer into natural killer
cells by nucleofection. J Immunol Methods 274:245-256 (2003);
Schroers R, et al., Gene transfer into human T lymphocytes and
natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp
Hematol 32:536-546 (2004)]. We achieved stable expression of
chimeric receptors in primary CD56.sup.+ CD3.sup.- NK cells by
using an RD114-pseudotyped retroviral vector and specifically
expanding primary CD56.sup.+ CD3.sup.- NK cells before they were
exposed to the retrovirus, a step that allowed highly efficient
gene expression. Although several cytokines such as IL-2, IL-12 and
IL-15 have been reported to stimulate NK cells [Carson W E, et al.,
A potential role for interleukin-15 in the regulation of human
natural killer cell survival J Clin Invest. 99:937-943 (1997);
Trinchieri G, et al., Response of resting human peripheral blood
natural killer cells to interleukin 2 J Exp Med 1984; 160:1147-1169
(1984); Naume B, et al., A comparative study of IL-12 (cytotoxic
lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on
immunomagnetically purified CD56+ NK cells. J Immunol 148:2429-2436
(1992)], their capacity to induce proliferation of resting
CD56.sup.+ CD3 cells has been poor, unless accessory cells are
present in the cultures. Perussia et al. Nat Immun Cell Growth
Regul 6:171-188 (1987), found that contact with irradiated
B-lymphoblastoid cells induced as high as a 25-fold expansion of NK
cells after 2 weeks of stimulation, while Miller et al. Blood;
80:2221-2229 (1992) reported an approximate 30-fold expansion of NK
cells after 18 days of culture with 1000 U/mL IL-2 and monocytes.
However, these culture conditions are likely to promote the growth
of CD3.sup.+ T lymphocytes as well as NK cells. Since our ultimate
aim is to generate pure preparations for out donor NK cells devoid
of CD3.sup.+ T lymphocytes, that can be infused into recipients of
allogeneic hematopoietic stem cell transplants, we searched for
methods that would maximize NK cell expansion without producing
T-cell mitogenicity.
[0174] Contact with K562 cells (which lack MHC-class 1 molecule
expression and hence do not trigger KIR-mediated inhibitory signals
in NK cells) is known to augment NK cell proliferation in response
to IL-15. We found that membrane-bound IL-15 and 4-1BBL,
coexpressed by K562 cells, acted synergistically to augment
K562-specific NK stimulatory capacity, resulting in vigorous
expansion of peripheral blood CD56.sup.+ CD3.sup.- NK cells without
concomitant growth of T lymphocytes. After 2-3 weeks of culture, we
observed NK cell expansions of up to 10,000-fold, and virtually
pure populations of NK cells could be obtained, even without the
need for T-cell depletion in some cases. NK cells expanded in this
system retained the immunophenotypic diversity seen among
peripheral blood subsets of NK cells, as well as their natural
cytotoxicity against sensitive target cells, even after
transduction with different chimeric receptors. Hence, this system
should help studies of NK cell biology which require specific cell
expansion and/or gene transduction, but it should also be adaptable
to clinical applications after generating K562 mb 15-4 1 BBL cells
that comply with current good manufacturing practices for clinical
trials. Recently, Harada et al. reported that expansions of
CD56.sup.+ CD3.sup.- cells (up to 400-fold after 2 weeks) were
apparently superior after contact with another HLA class I-negative
cell line, the Wilms tumor cell line HFWT [Harada H, Saijo K,
Watanabe S, et al. Selective expansion of human natural killer
cells from peripheral blood mononuclear cells by the cell line,
HFWT. Jpn J Cancer Res 93:313 (2002)]. Future studies should
determine whether HFWT cells express 41BBL or whether enforced
expression of 4-1BBL together with IL-15 results in a greater
specific expansion of NK cells than seen with modified K562
cells.
[0175] In the context of allogeneic hematopoietic stem cell
transplantation, infusions of activated donor T cells would carry
an unacceptably high risk of severe GvHD, particularly in
recipients of haploidentical or mismatched transplants. By
contrast, infusions of pure CD56 CD3 NK cells should not impose
that risk [Ruggeri L, et al., Effectiveness of donor natural killer
cell alloreactivity in mismatched hematopoietic transplants.
Science 295:2097-2100 (2002)]. Most clinical studies of the
therapeutic effects of NK cells have been performed in an
autologous setting and have yielded only moderately promising
results [Farag S S, et al., Natural killer cell receptors: new
biology and insights into the graft-versus-leukemia effect. Blood
100:1935-1947 (2002); Chiorean E G, Miller J S. The biology of
natural killer cells and implications for therapy of human disease.
J Hematother Stem Cell Res 10:451-463 (2001)]. This is not
surprising because NK cell activity is inhibited by surface
receptors that recognize autologous HLA molecules expressed by both
normal and neoplastic cells. Allogeneic NK cells may be more
effective, but even in an allogeneic setting the capacity of NK
cells to kill malignant lymphoid cells is generally modest and
often negligible [Caligiuri M A, Velardi A, Scheinberg D A,
Borrello I M. Immunotherapeutic approaches for hematologic
malignancies. Hematology (Am Soc Hematol Educ Program) 337-353
(2004)]. Leung et al. [J Immunol 172:644-650 (2004)] detected NK
cytotoxicity against an ALL cell line expressing particularly low
levels of inhibitory HLA molecules, but cytotoxicity was much lower
than that observed against the NK-cell target K562: only about 50%
of the ALL cells were killed at an effector:target ratio of 40:1.
In that study, RS4;11 cells, which express HLA-C alleles that bind
the most commonly expressed KIRs, were NK-resistant, whereas these
cells, as well as autologous leukemic cells, were highly sensitive
to NK cells expressing anti-CD 19 signaling receptors in our study.
NK cells expressing signaling chimeric receptors have much more
powerful antileukemic activity than unmodified NK cells, and can
kill target cells irrespective of their HLA profile. An increased
understanding of the signals leading to immune cell activation,
together with progress in gene cloning and transfer, have made the
treatment of cancer with "adoptively acquired immunity" a realistic
goal. Clinical precedents, such as administration of T-cell clones
that target cytomegalovirus epitopes [Walter E A, et al.,
Reconstitution of cellular immunity against cytomegalovirus in
recipients of allogeneic bone marrow by transfer of T-cell clones
from the donor. N Engl J Med 1995; 333:1038-1044 (1995)] or
EBV-specific antigens [Rooney C M, et al., Use of gene-modified
virus-specific T lymphocytes to control Epstein-Barr-virus-related
lymphoproliferation. Lancet 345:9-13 (1995)], attest to the
clinical feasibility of adoptive immune cell therapy. Nonetheless,
there are potential limitations that may affect the effectiveness
of cell therapy guided by chimeric receptors. One is that the
murine scFv portion of the chimeric receptor or the fusion sites of
the human regions that compose it may trigger a host immune
response leading to elimination of the modified cells [Sadelain M,
et al., Targeting tumours with genetically enhanced T lymphocytes.
Nat Rev Cancer 3:35-45 (2003)]. Although the impact of such an
event in a clinical setting remains to be determined, we anticipate
that immune responses against modified NK cells will be limited in
immune-suppressed patients after hematopoietic stem cell
transplantation. Another potential limitation is that adoptively
transferred cells may have inadequate persistence in vivo, although
a recent study showed that NK cells obtained from haploidentical
donors and activated ex vivo could expand in patients when infused
after administration of high-dose cyclophosphamide and fludarabine,
which caused an increased in endogenous IL-15 [Miller J S, et al.,
Successful adoptive transfer and in vivo expansion of human
haploidentical NK cells in cancer patients. Blood; in press
(2005)]. We speculate that such expansions would also occur with
genetically-modified NK cells, and suggest that further studies to
identify signaling molecules that promote NK cell proliferation
when incorporated into chimeric receptors are warranted. In
patients at a high risk of leukemia or lymphoma relapse, the
expected benefits of genetically-modified NK cells will outweigh
the risk of insertional oncogenesis posed by the use of
retroviruses for chimeric receptor transduction [Baum C, et al.,
Side effects of retroviral gene transfer into hematopoietic stem
cells. Blood 101:2099-2114 (2003)]. We also predict that the
coexpression of suicide genes will become a useful safety measure
in clinical studies [Marktel S, et al., Immunologic potential of
donor lymphocytes expressing a suicide gene for early immune
reconstitution after hematopoietic T-cell-depleted stem cell
transplantation. Blood 101:1290-1298 (2003)]; this strategy would
also ensure that the elimination of normal CD19.sup.+ B-lineage
cells is only temporary.
[0176] Novel therapies that bypass cellular mechanisms of drug
resistance are urgently needed for patients with refractory
leukemia and lymphoma. NK cell alloreactivity is a powerful new
tool for improving the therapeutic potential of allogeneic
hematopoietic stem cell transplantation. The results of this study
indicate that signaling receptors can enhance the efficacy of NK
cell alloreactivity and widen its applicability. We envisage
initial clinical trials in which donor NK cells, collected by
apheresis, are expanded ex vivo as described here, transduced with
chimeric receptors and then infused after transplantation in
patients with B-lineage ALL. The target molecule for the chimeric
receptors, CD 19, was selected because it is one of the most widely
expressed surface antigens among B-cell malignancies, including
ALL, CLL and NHL. In these malignancies, CD19 is highly expressed
on the surface of virtually all cells but has limited or no
expression in normal tissues [Campana D, Behm F G.
Immunophenotyping of leukemia. J Immunol Methods 243:59-75 (2000)].
However, the NK-cell strategy of immunotherapy we describe would
not have to be directed to the CD19 antigen, but could be applied
to any of the numerous molecules identified as potential targets
for chimeric receptor-based cell therapy in cancer patients.
9.4 Example 4
[0177] Specific examples of a chimeric receptor comprising an
anti-CD19 single chain variable fragment (scFv) domain, a
transmembrane domains, and a cytoplasmic domain comprising a 4-1BB
signaling domain and a CD3.zeta. signaling domain, and
polynucleotides that encode such chimeric receptors, are provided
herein.
Anti-CD19-BB-.zeta. Chimeric Receptors
[0178] The specific chimeric receptors described herein each
comprise a CD 19-binding extracellular receptor domain, a
transmembrane domain, and a cytoplasmic domain comprising a 4-1BB
(CD137) signaling domain and a CD3.zeta. signaling domain.
Stimulation through anti-CD19-BB-.zeta. chimeric receptors may
result in one or more effector activities, including recruiting
protein kinases, activating kinase pathways and cascades,
stimulating production of transcription factors, promoting signal
transduction, and/or triggering secretion of cytokines and/or
chemokines, leading to T-cell activation, prolonged T-cell response
and growth, induction of cytolytic activity, increased target cell
apoptosis, and/or enhanced or sustained cytotoxicity and anti-tumor
capacity against target cells, thereby providing a therapeutic
response useful for treatment, protection against, and/or
amelioration of cancer and infectious diseases.
[0179] A specific embodiment of an anti-CD19-BB-.zeta. chimeric
receptor having the amino acid sequence of SEQ ID No. 6 was
designed and constructed. In this specific embodiment, the
anti-CD19-BB-.zeta. chimeric receptor polypeptide comprises: (1)
the amino acid sequence of the CD8.alpha. signal peptide of SEQ ID
No. 8; (2) the amino acid sequence of the anti-CD19 single-chain
variable fragment of SEQ ID No. 10, comprising a light chain
variable domain and a heavy chain variable domain; (3) the amino
acid sequence of the CD8.alpha. hinge region of SEQ. ID. No. 12;
(4) the amino acid sequence of the CD8.alpha. transmembrane domain
of SEQ ID No. 14; (5) the amino acid sequence of the 4-1BB
signaling domain of SEQ ID No. 16; and (6) the amino acid sequence
of the CD3.zeta. signaling domain of SEQ ID No. 18. This specific
embodiment of the anti-CD19-BB-.zeta. chimeric receptor is referred
to in the following paragraph as the "Anti-CD19-BB-.zeta. Chimeric
Receptor."
[0180] The anti-CD19-BB-.zeta. chimeric receptors of the invention
also include derivatives of the Anti-CD19-BB-.zeta. Chimeric
Receptor described above. As used herein, a "derivative" of the
Anti-CD19-BB-.zeta. Chimeric Receptor protein or polypeptide, or of
a domain thereof, refer to: (a) a polypeptide that is at least 40%,
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%
identical to the Anti-CD19-BB-.zeta. Chimeric Receptor or a domain
thereof; (b) a polypeptide encoded by a nucleic acid sequence that
is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 98% or 99% identical a nucleic acid sequence encoding the
Anti-CD19-BB-.zeta. Chimeric Receptor or a domain thereof; (c) a
polypeptide that contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20 or more amino acid changes (i.e.,
mutations, additions, deletions and/or substitutions) relative to
the Anti-CD19-BB-.zeta. Chimeric Receptor or a domain thereof; (d)
a polypeptide encoded by nucleic acids can hybridize under high,
moderate or typical stringency hybridization conditions to nucleic
acids encoding the Anti-CD19-BB-.zeta. Chimeric Receptor or a
domain thereof; (e) a polypeptide encoded by a nucleic acid
sequence that can hybridize under high, moderate or typical
stringency hybridization conditions to a nucleic acid sequence
encoding a fragment of the Anti-CD19-BB-.zeta. Chimeric Receptor or
a domain thereof of at least 20 contiguous amino acids, at least 30
contiguous amino acids, at least 40 contiguous amino acids, at
least 50 contiguous amino acids, at least 75 contiguous amino
acids, at least 100 contiguous amino acids, at least 125 contiguous
amino acids, or at least 150 contiguous amino acids; or (f) a
fragment of the Anti-CD19-BB-.zeta. Chimeric Receptor or a domain
thereof. In one embodiment, a derivative is isolated or purified.
In specific embodiments, a derivative retains one or more functions
of the Anti-CD19-BB-.zeta. Chimeric Receptor or functions of a
native protein from which a domain of the Anti-CD19-BB-.zeta.
Chimeric Receptor was derived.
[0181] The anti-CD19-BB-.zeta. chimeric receptor derivatives of the
invention retain one or more activities of an anti-CD19-BB-.zeta.
chimeric receptor. In particular, an anti-CD19-BB-.zeta. chimeric
receptor derivative of the invention retains the ability to bind CD
19 and trigger signaling like an anti-CD19-BB-.zeta. chimeric
receptor.
[0182] In one embodiment, an anti-CD19-BB-.zeta. chimeric receptor
or derivative thereof comprises a CD3.zeta. domain that retains the
ability to trigger signaling like the native CD3-.zeta.. In another
embodiment, an anti-CD19-BB-.zeta. chimeric receptor or derivative
thereof comprises a 4-1BB derivative domain that retains the
ability to trigger signaling like the native 4-1BB. In preferred
embodiments, anti-CD19-BB-.zeta. chimeric receptors and derivatives
result in one or more effector activities, including recruiting
protein kinases, activating kinase pathways and cascades,
stimulating production of transcription factors, promoting signal
transduction, and/or triggering secretion of cytokines and/or
chemokines, leading to T cell activation, prolonged T cell response
and growth, induction of cytolytic activity, increased target cell
apoptosis, and/or enhanced or sustained cytotoxicity and anti-tumor
capacity against target cells. Such anti-CD19-BB-.zeta. chimeric
receptors can thus provide a therapeutic response useful for
treatment, protection against, and/or amelioration of one or more
symptoms of a cancer and infectious disease.
[0183] In a specific embodiment of the invention, an
anti-CD19-BB-.zeta. chimeric receptor polypeptide comprises the
amino acid sequence of SEQ ID No. 20, wherein the CD3.zeta.
signaling domain comprises the amino acid sequence of SEQ ID No.
22.
[0184] Percent identity can be determined using any method known to
one of skill in the art. In a specific embodiment, the percent
identity is determined using the "Best Fit" or "Gap" program of the
Sequence Analysis Software Package (Version 10; Genetics Computer
Group, Inc., University of Wisconsin Biotechnology Center, Madison,
Wis.). Information regarding hybridization conditions (e.g., high,
moderate, and typical stringency conditions) have been described,
see, e.g., U.S. Patent Application Publication No. US 2005/0048549
(e.g., paragraphs 72-73).
Polynucleotides Encoding Anti-CD19-BB-.zeta. Chimeric Receptors
[0185] A specific example of a polynucleotide encoding an
anti-CD19-BB-.zeta. chimeric receptor was constructed. A
polynucleotide having the nucleotide sequence of SEQ ID No. 5,
encoding a polypeptide having the amino acid sequence SEQ ID No. 6,
was constructed using the methods available in the art (see, e.g.,
Example 1). The specific anti-CD19-BB-.zeta. chimeric receptor
polynucleotide comprises: (1) the nucleic acid sequence of SEQ. ID.
No. 7 encoding a CD8.alpha. signal peptide; (2) the nucleic acid
sequence of SEQ ID No. 9 encoding an anti-CD19 single-chain
variable fragment which comprises a light chain variable domain and
a heavy chain variable domain; (3) the nucleic acid sequence of
SEQ. ID. No. 11 encoding a CD8a hinge region; (4) the nucleic acid
sequence of SEQ ID No. 13 encoding a CD8a transmembrane domain; (5)
the nucleic acid sequence of SEQ ID No. 15 encoding the 4-1BB
signaling domain; and (6) the nucleic acid sequence of SEQ ID No.
17 comprising a CD3.zeta. signaling domain.
[0186] Another specific example of an anti-CD19-BB-.zeta. chimeric
receptor polynucleotide is one that encodes a polypeptide having
the amino acid sequence of SEQ ID No. 20, wherein the CD3.zeta.
signaling domain comprises the amino acid sequence of SEQ ID No.
22. In one specific embodiment, the anti-CD19-BB-.zeta. chimeric
receptor polynucleotide comprises the nucleotide sequence of SEQ ID
No. 19, and/or the CD3.zeta. signaling domain comprises the nucleic
acid sequence of SEQ ID No. 21. A specific example of an
anti-CD19-BB-.zeta. chimeric receptor has the nucleotide sequence
of SEQ ID No. 19 comprising the following sequence: (1) the nucleic
acid sequence of SEQ. ID. No. 7 encoding a CD8.alpha.. signal
peptide; (2) the nucleic acid sequence of SEQ ID No. 9 encoding an
anti-CD19 single-chain variable fragment which comprises a light
chain variable domain and a heavy chain variable domain; (3) the
nucleic acid sequence of SEQ. ID. No. 11 encoding a CD8.alpha.
hinge region; (4) the nucleic acid sequence of SEQ ID No. 13
encoding a CD8.alpha. transmembrane domain; (5) the nucleic acid
sequence of SEQ ID No. 15 encoding the 4-1BB signaling domain; and
(6) the nucleic acid sequence of SEQ ID No. 21 comprising a
CD3.zeta. signaling domain.
[0187] The invention includes nucleotide sequences of fragments,
variants (e.g., modified forms), derivatives, or functional
equivalents of an anti-CD19-BB-.zeta. chimeric receptor or a part
thereof (e.g., an anti-CD19-BB-.zeta. chimeric receptor comprising
a fragment, variant, derivative, or functional equivalent of an
anti-CD19 scFv domain, a 4-1BB (CD137) domain, and/or a CD3.zeta.
domain) that retains the ability to bind CD19 and enhance
cytotoxicity and antitumor capacity against target cells, promote
signal transduction, trigger secretion of cytokines and/or
chemokines, increase target cell apoptosis, and sustain
cytotoxicity against target cells. A "form" of an
anti-CD19-BB-.zeta. chimeric receptor is intended to mean a
chimeric receptor that shares a significant homology with the
anti-CD19-BB-.zeta. chimeric receptor and is capable of enhancing
the cytotoxicity and antitumor activity against target cells. A
"functionally equivalent" anti-CD19-BB-.zeta. chimeric receptor
polynucleotide is understood within the scope of the present
invention to refer to a polynucleotide which substantially shares
at least one major functional property with the polynucleotides
mentioned above. As such, these polynucleotides are useful for
treatment, protection against, and/or amelioration of cancer and
infectious diseases.
[0188] Nucleic acid sequences encoding native anti-CD19 binding
domains, native 4-1BB (CD137) signaling domains, and/or native
CD3.zeta. signaling domains are known in the art and have been
described in the literature. For example, the nucleic acid
sequences encoding native anti-CD19 binding domains, native 4-1BB
signaling domains, and native CD3.zeta. signaling domains useful
for constructing an anti-CD19-BB.zeta. chimeric receptor can be
found in publicly available publications and databases, e.g.,
National Center for Biotechnology Information website at
ncbi.nlm.nih.gov. Cloning techniques well known in the art can be
used to generate nucleic acids encoding the anti-CD19-BB.zeta.
chimeric receptors of the invention. See, e.g., Ausubel et al.,
Current Protocols in Molecular Biology, John Wiley and Sons, Inc.
(1995); Sambrook et al., Molecular Cloning, A Laboratory Manual (2d
ed.), Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989);
Birren et al., Genome Analysis: A Laboratory Manual, volumes 1
through 4, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
(1997-1999).
[0189] In specific embodiments, a polynucleotide encoding an
anti-CD19 binding domain comprises: (a) a nucleic acid sequence
that is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 98% or 99% identical to the naturally occurring nucleic
acid sequence encoding a native anti-CD19 binding domain
polypeptide; (b) a nucleic acid sequence encoding a polypeptide
that is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 98% or 99% identical the amino acid sequence of a native
anti-CD19 binding domain polypeptide; (c) a nucleic acid sequence
that contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20 or more nucleic acid base mutations (e.g.,
additions, deletions and/or substitutions) relative to the
naturally occurring nucleic acid sequence encoding a native
anti-CD19 binding domain polypeptide; (d) a nucleic acid sequence
that hybridizes under high, moderate or typical stringency
hybridization conditions to a naturally occurring nucleic acid
sequence encoding a native anti-CD19 binding domain polypeptide;
(e) a nucleic acid sequence that hybridizes under high, moderate or
typical stringency hybridization conditions to a fragment of a
naturally occurring nucleic acid sequence encoding a native
anti-CD19 binding domain polypeptide; and (f) a nucleic acid
sequence encoding a fragment of a naturally occurring nucleic acid
sequence encoding a native anti-CD19 binding domain polypeptide. In
another specific embodiment, the polynucleotide is an isolated or
purified polynucleotide.
[0190] In specific embodiments, a polynucleotide encoding a 4-1BB
signaling domain comprises: (a) a nucleic acid sequence that is at
least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98% or 99% identical to the naturally occurring nucleic acid
sequence encoding a native 4-1BB polypeptide; (b) a nucleic acid
sequence encoding a polypeptide that is at least 40%, 45%, 50%,
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identical
the amino acid sequence of a native 4-1BB signaling domain
polypeptide; (c) a nucleic acid sequence that contains 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more
nucleic acid base mutations (e.g., additions, deletions and/or
substitutions) relative to the naturally occurring nucleic acid
sequence encoding a native 4-1BB signaling domain polypeptide; (d)
a nucleic acid sequence that hybridizes under high, moderate or
typical stringency hybridization conditions to a naturally
occurring nucleic acid sequence encoding a native 4-1BB signaling
domain polypeptide; (e) a nucleic acid sequence that hybridizes
under high, moderate or typical stringency hybridization conditions
to a fragment of a naturally occurring nucleic acid sequence
encoding a native 4-1BB signaling domain polypeptide; and (f) a
nucleic acid sequence encoding a fragment of a naturally occurring
nucleic acid sequence encoding a native 4-1BB signaling domain
polypeptide. In another specific embodiment, the polynucleotide is
an isolated or purified polynucleotide.
[0191] In specific embodiments, a polynucleotide encoding CD3.zeta.
signaling domain comprises: (a) a nucleic acid sequence that is at
least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98% or 99% identical to the naturally occurring nucleic acid
sequence encoding a native CD3.zeta. signaling domain polypeptide;
(b) a nucleic acid sequence encoding a polypeptide that is at least
40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or
99% identical the amino acid sequence of a native CD3.zeta.
signaling domain olypeptide; (c) a nucleic acid sequence that
contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20 or more nucleic acid base mutations (e.g., additions,
deletions and/or substitutions) relative to the naturally occurring
nucleic acid sequence encoding a native CD3.zeta. signaling domain
polypeptide; (d) a nucleic acid sequence that hybridizes under
high, moderate or typical stringency hybridization conditions to a
naturally occurring nucleic acid sequence encoding a native
CD3.zeta. signaling domain polypeptide; (e) a nucleic acid sequence
that hybridizes under high, moderate or typical stringency
hybridization conditions to a fragment of a naturally occurring
nucleic acid sequence encoding a native CD3.zeta. signaling domain
polypeptide; and (f) a nucleic acid sequence encoding a fragment of
a naturally occurring nucleic acid sequence encoding a native
CD3.zeta. signaling domain polypeptide. In another specific
embodiment, the polynucleotide is an isolated or purified
polynucleotide.
[0192] In a specific embodiment, a nucleic acid sequence encoding
an anti-CD19 binding domain polypeptide is a derivative of a
naturally occurring nucleic acid sequence encoding a native human
anti-CD19 polypeptide. In another embodiment, a nucleic acid
sequence encoding an anti-CD19 binding domain polypeptide is a
derivative of a naturally occurring nucleic acid sequence encoding
an immature or precursor form of a native human anti-CD19
polypeptide. In another embodiment, a nucleic acid sequence
encoding an anti-CD19 binding domain polypeptide is a derivative of
a naturally occurring nucleic acid sequence encoding a mature form
of a native human anti-CD19 polypeptide. In another embodiment, a
nucleic acid sequence encodes an anti-CD19 derivative described
herein.
[0193] In a specific embodiment, a nucleic acid sequence encoding a
4-1BB signaling domain polypeptide is a derivative of a naturally
occurring nucleic acid sequence encoding a native human 4-1BB
signaling polypeptide. In another embodiment, a nucleic acid
sequence encoding a 4-1BB signaling domain polypeptide is a
derivative of a naturally occurring nucleic acid sequence encoding
an immature or precursor form of a native human 4-1BB polypeptide.
In another embodiment, a nucleic acid sequence encoding a 4-1BB
signaling domain polypeptide is a derivative of a naturally
occurring nucleic acid sequence encoding a mature form of a native
human 4-1B polypeptide. In another embodiment, a nucleic acid
sequence encodes a 4-1BB derivative described herein.
[0194] In a specific embodiment, a nucleic acid sequence encoding a
CD3.zeta. signaling domain polypeptide is a derivative of a
naturally occurring nucleic acid sequence encoding a native human
CD3.zeta. polypeptide. In another embodiment, a nucleic acid
sequence encoding a CD3.zeta. signaling domain polypeptide is a
derivative of a naturally occurring nucleic acid sequence encoding
an immature or precursor form of a native human CD3.zeta.
polypeptide. In another embodiment, a nucleic acid sequence
encoding a CD3.zeta. signaling domain polypeptide is a derivative
of a naturally occurring nucleic acid sequence encoding a mature
form of a native human CD3.zeta. polypeptide. In another
embodiment, a nucleic acid sequence encodes a CD3.zeta. signaling
domain derivative described herein.
[0195] In certain embodiments, polynucleotides include
codon-optimized nucleic acid sequences that encode native anti-CD19
binding domain polypeptides, 4-1BB signaling domain polypeptides,
or CD3.zeta. signaling domain polypeptides, including mature and
immature forms. In other embodiments, polynucleotides include
nucleic acids that encode anti-CD 19 binding domain, 4-1BB
signaling domain, or CD3.zeta. signaling domain RNA transcripts
containing mutations that eliminate potential splice sites and
instability elements (e.g., A/T or A/U rich elements) without
affecting the amino acid sequence to increase the stability of the
CD3.zeta. RNA transcripts.
[0196] In certain embodiments, nucleic acid sequences encode a
4-1BB signaling domain polypeptide that retains at least 25%, 30%,
35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98% or 99%, or in the range of between 25% to 50%, 25% to 75%, 25%
to 98%, 50% to 75%, or 75% to 100% of a function of a native 4-1BB
polypeptide, such as enhancing cytotoxicity and anti-tumor capacity
against target cells, promoting signal transduction, increasing
cytokine and/or chemokine secretion, increasing target cell
apoptosis, or sustaining cytotoxicity against target cells, for
example, as measured by assays well known in the art.
[0197] In certain embodiments, nucleic acid sequences encode a
CD3.zeta. signaling domain polypeptide that retains at least 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 98% or 99%, or in the range of between 25% to 50%, 25% to 75%,
25% to 98%, 50% to 75%, or 75% to 100% of a function of a native
CD3.zeta. polypeptide, such as enhancing cytotoxicity and
anti-tumor capacity against target cells, promoting signal
transduction, increasing cytokine and/or chemokine secretion,
increasing target cell apoptosis, or sustaining cytotoxicity
against target cells, for example, as measured by assays well known
in the art.
[0198] In certain embodiments, nucleic acid sequences encode an
anti-CD19 binding domain polypeptide that retains at least 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 98% or 99%, or in the range of between 25% to 50%, 25% to 75%,
25% to 98%, 50% to 75%, or 75% to 100% of a function of a native
CD19-binding polypeptide, such as recognizing and binding
CD19-positive B cells.
[0199] In some embodiments, nucleic acid sequences encode a 4-1BB
signaling domain polypeptide that retains at least 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or
99%, or in the range of between 25% to 50%, 25% to 75%, 25% to 98%,
50% to 75%, or 75% to 100% of the ability to activate or induce one
or more of the signal transduction pathways induced when a native
ligand of 4-1BB signaling domain (4-1BBL, also termed CD137L) binds
to a native 4-1BB polypeptide, as measured by assays well-known in
the art. The one or more signal transduction pathways induced by
binding of a 4-1BBL to 4-1BB can be measured by, e.g., assessing
the activation of a signal transduction moiety (non-limiting
examples of which are TRAF1, TRAF2, TRAF3, ASK1, p38 MAPKs
(Mitogen-Activated Protein Kinase), SAPK (Stress-Activated Protein
Kinase)/JNK (c-Jun Kinase), ERK1/2 (Extracellular Signal-Regulated
Kinase-1/2), NIK(NF-KappaB-Inducing Kinase), IKKs (Inhibitor of
KappaB Kinase-Alpha), NF-KappaB (Nuclear Factor-KappaB), germinal
center kinase (GCK)) using techniques such as antibody microarray,
ELISAs, Western blots, electromobility shift assays, and other
immunoassays. In a specific embodiment, nucleic acid sequences
encode a 4-1BB signaling domain polypeptide that retains at least
25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 98% or 99%, or in the range of between 25% to 50%, 25% to
75%, 25% to 98%, 50% to 75%, or 75% to 100% of the ability to
activate or induce one or more of the signal transduction pathways
induced by binding of a native 4-1BBL to 4-1BB.
[0200] In some embodiments, nucleic acid sequences encode a
CD3.zeta. signaling domain polypeptide that retains at least 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 98% or 99%, or in the range of between 25% to 50%, 25% to 75%,
25% to 98%, 50% to 75%, or 75% to 100% of the ability to stabilize
the surface membrane expression of CD 19 and activate or induce one
or more of the signal transduction pathways induced when a native
ligand of 4-1BB signaling domain (4-1BBL, also termed CD137L) binds
to a native 4-1BB signaling domain polypeptide, as measured by
assays well-known in the art. The one or more signal transduction
pathways induced by binding of a 4-1BBL to 4-1BB signaling domain
can be measured by, e.g., assessing the activation of a signal
transduction moiety (non-limiting examples of which are TRAF1,
TRAF2, TRAF3, ASK1, p38 MAPKs (Mitogen-Activated Protein Kinase),
SAPK (Stress-Activated Protein Kinase)/JNK (c-Jun Kinase), ERK1/2
(Extracellular Signal-Regulated Kinase-1/2), NIK(NF-KappaB-Inducing
Kinase), IKKs (Inhibitor of KappaB Kinase-Alpha), NF-KappaB
(Nuclear Factor-KappaB), germinal center kinase (GCK)) using
techniques such as antibody microarray, ELISAs, Western blots,
electromobility shift assays, and other immunoassays. In a specific
embodiment, nucleic acid sequences encode a CD3.zeta. polypeptide
that retains at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%, or in the range of
between 25% to 50%, 25% to 75%, 25% to 98%, 50% to 75%, or 75% to
100% of the ability to activate or induce one or more of the signal
transduction pathways induced by binding of a native 4-1BBL to
4-1BB.
[0201] In some embodiments, nucleic acid sequences encode a
CD3.zeta. polypeptide that retains at least 25%, 30%, 35%, 40%,
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%,
or in the range of between 25% to 50%, 25% to 75%, 25% to 98%, 50%
to 75%, or 75% to 100% of the ability to activate or induce one or
more of the signal transduction pathways induced when a native
ligand of 4-1BB signaling domain (4-1BBL, also termed CD137L) binds
to a native 4-1BB signaling domain polypeptide, as measured by
assays well-known in the art. The one or more signal transduction
pathways induced by binding of a 4-1BBL to 4-1BB signaling domain
can be measured by, e.g., assessing the activation of a signal
transduction moiety (non-limiting examples of which are TRAF1,
TRAF2, TRAF3, ASK1, p38 MAPKs (Mitogen-Activated Protein Kinase),
SAPK (Stress-Activated Protein Kinase)/JNK (c-Jun Kinase), ERK1/2
(Extracellular Signal-Regulated Kinase-1/2), NIK(NF-KappaB-Inducing
Kinase), IKKs (Inhibitor of KappaB Kinase-Alpha), NF-KappaB
(Nuclear Factor-KappaB), germinal center kinase (GCK)) using
techniques such as antibody microarray, ELISAs, Western blots,
electromobility shift assays, and other immunoassays. In a specific
embodiment, nucleic acid sequences encode a CD3.zeta. polypeptide
that retains at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%, or in the range of
between 25% to 50%, 25% to 75%, 25% to 98%, 50% to 75%, or 75% to
100% of the ability to activate or induce one or more of the signal
transduction pathways induced by binding of a native 4-1BBL to
4-1BB.
[0202] In certain embodiments, nucleic acid sequences encode a
4-1BB signaling domain polypeptide that has a higher affinity for a
native ligand of 4-1BB signaling domain than a native 4-1BB
signaling domain polypeptide for the same ligand, as measured by
assays/techniques well known in the art, e.g., ELISA, Biacore, or
co-immunoprecipitation. In a specific embodiment, nucleic acid
sequences encode an 4-1BB signaling domain polypeptide that binds
to a native ligand of 4-1BB signaling domain with 0.5 logs, 1 log,
1.5 logs, 2 logs, 2.5 logs, or 3 logs higher affinity than a native
4-1BB polypeptide binds to the same receptor, as measured by
assays/techniques well known in the art, e.g., ELISA, Biacore, or
co-immunoprecipitation.
[0203] All of the above U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, foreign
patent applications and non-patent publications referred to in this
specification, including but not limited to U.S. patent application
Ser. No. 09/960,264, filed Sep. 20, 2001; and U.S. application Ser.
No. 10/981,352, filed Nov. 4, 2004, are incorporated herein by
reference, in their entirety. All of references, patents, patent
applications, etc. cited above, are incorporated herein in their
entirety.
Sequence CWU 1
1
2211935DNAHomo sapiensCDS(129)..(893) 1agaccaagga gtggaaagtt
ctccggcagc cctgagatct caagagtgac atttgtgaga 60ccagctaatt tgattaaaat
tctcttggaa tcagctttgc tagtatcata cctgtgccag 120atttcatc atg gga aac
agc tgt tac aac ata gta gcc act ctg ttg ctg 170 Met Gly Asn Ser Cys
Tyr Asn Ile Val Ala Thr Leu Leu Leu 1 5 10 gtc ctc aac ttt gag agg
aca aga tca ttg cag gat cct tgt agt aac 218Val Leu Asn Phe Glu Arg
Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn 15 20 25 30 tgc cca gct ggt
aca ttc tgt gat aat aac agg aat cag att tgc agt 266Cys Pro Ala Gly
Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser 35 40 45 ccc tgt
cct cca aat agt ttc tcc agc gca ggt gga caa agg acc tgt 314Pro Cys
Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys 50 55 60
gac ata tgc agg cag tgt aaa ggt gtt ttc agg acc agg aag gag tgt
362Asp Ile Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys
65 70 75 tcc tcc acc agc aat gca gag tgt gac tgc act cca ggg ttt
cac tgc 410Ser Ser Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe
His Cys 80 85 90 ctg ggg gca gga tgc agc atg tgt gaa cag gat tgt
aaa caa ggt caa 458Leu Gly Ala Gly Cys Ser Met Cys Glu Gln Asp Cys
Lys Gln Gly Gln 95 100 105 110 gaa ctg aca aaa aaa ggt tgt aaa gac
tgt tgc ttt ggg aca ttt aac 506Glu Leu Thr Lys Lys Gly Cys Lys Asp
Cys Cys Phe Gly Thr Phe Asn 115 120 125 gat cag aaa cgt ggc atc tgt
cga ccc tgg aca aac tgt tct ttg gat 554Asp Gln Lys Arg Gly Ile Cys
Arg Pro Trp Thr Asn Cys Ser Leu Asp 130 135 140 gga aag tct gtg ctt
gtg aat ggg acg aag gag agg gac gtg gtc tgt 602Gly Lys Ser Val Leu
Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys 145 150 155 gga cca tct
cca gcc gac ctc tct ccg gga gca tcc tct gtg acc ccg 650Gly Pro Ser
Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro 160 165 170 cct
gcc cct gcg aga gag cca gga cac tct ccg cag atc atc tcc ttc 698Pro
Ala Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Ser Phe 175 180
185 190 ttt ctt gcg ctg acg tcg act gcg ttg ctc ttc ctg ctg ttc ttc
ctc 746Phe Leu Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu Leu Phe Phe
Leu 195 200 205 acg ctc cgt ttc tct gtt gtt aaa cgg ggc aga aag aaa
ctc ctg tat 794Thr Leu Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys
Leu Leu Tyr 210 215 220 ata ttc aaa caa cca ttt atg aga cca gta caa
act act caa gag gaa 842Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln
Thr Thr Gln Glu Glu 225 230 235 gat ggc tgt agc tgc cga ttt cca gaa
gaa gaa gaa gga gga tgt gaa 890Asp Gly Cys Ser Cys Arg Phe Pro Glu
Glu Glu Glu Gly Gly Cys Glu 240 245 250 ctg tgaaatggaa gtcaataggg
ctgttgggac tttcttgaaa agaagcaagg 943Leu 255 aaatatgagt catccgctat
cacagctttc aaaagcaaga acaccatcct acataatacc 1003caggattccc
ccaacacacg ttcttttcta aatgccaatg agttggcctt taaaaatgca
1063ccactttttt tttttttttg acagggtctc actctgtcac ccaggctgga
gtgcagtggc 1123accaccatgg ctctctgcag ccttgacctc tgggagctca
agtgatcctc ctgcctcagt 1183ctcctgagta gctggaacta caaggaaggg
ccaccacacc tgactaactt ttttgttttt 1243tgtttggtaa agatggcatt
tcaccatgtt gtacaggctg gtctcaaact cctaggttca 1303ctttggcctc
ccaaagtgct gggattacag acatgaactg ccaggcccgg ccaaaataat
1363gcaccacttt taacagaaca gacagatgag gacagagctg gtgataaaaa
aaaaaaaaaa 1423aaagcatttt ctagatacca cttaacaggt ttgagctagt
ttttttgaaa tccaaagaaa 1483attatagttt aaattcaatt acatagtcca
gtggtccaac tataattata atcaaaatca 1543atgcaggttt gttttttggt
gctaatatga catatgacaa taagccacga ggtgcagtaa 1603gtacccgact
aaagtttccg tgggttctgt catgtaacac gacatgctcc accgtcaggg
1663gggagtatga gcagagtgcc tgagtttagg gtcaaggaca aaaaacctca
ggcctggagg 1723aagttttgga aagagttcaa gtgtctgtat atcctatggt
cttctccatc ctcacacctt 1783ctgcctttgt cctgctccct tttaagccag
gttacattct aaaaattctt aacttttaac 1843ataatatttt ataccaaagc
caataaatga actgcatatg aaaaaaaaaa aaaaaaaaaa 1903aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa aa 19352255PRTHomo sapiens 2Met Gly Asn Ser
Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu 1 5 10 15 Asn Phe
Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro 20 25 30
Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys 35
40 45 Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp
Ile 50 55 60 Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu
Cys Ser Ser 65 70 75 80 Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly
Phe His Cys Leu Gly 85 90 95 Ala Gly Cys Ser Met Cys Glu Gln Asp
Cys Lys Gln Gly Gln Glu Leu 100 105 110 Thr Lys Lys Gly Cys Lys Asp
Cys Cys Phe Gly Thr Phe Asn Asp Gln 115 120 125 Lys Arg Gly Ile Cys
Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys 130 135 140 Ser Val Leu
Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro 145 150 155 160
Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro Pro Ala 165
170 175 Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Ser Phe Phe
Leu 180 185 190 Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu Leu Phe Phe
Leu Thr Leu 195 200 205 Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys
Leu Leu Tyr Ile Phe 210 215 220 Lys Gln Pro Phe Met Arg Pro Val Gln
Thr Thr Gln Glu Glu Asp Gly 225 230 235 240 Cys Ser Cys Arg Phe Pro
Glu Glu Glu Glu Gly Gly Cys Glu Leu 245 250 255 32350DNAMus
musculusCDS(146)..(916)misc_feature(1253)..(1255)n is a, c, g, or t
3atgtccatga actgctgagt ggataaacag cacgggatat ctctgtctaa aggaatatta
60ctacaccagg aaaaggacac attcgacaac aggaaaggag cctgtcacag aaaaccacag
120tgtcctgtgc atgtgacatt tcgcc atg gga aac aac tgt tac aac gtg gtg
172 Met Gly Asn Asn Cys Tyr Asn Val Val 1 5 gtc att gtg ctg ctg cta
gtg ggc tgt gag aag gtg gga gcc gtg cag 220Val Ile Val Leu Leu Leu
Val Gly Cys Glu Lys Val Gly Ala Val Gln 10 15 20 25 aac tcc tgt gat
aac tgt cag cct ggt act ttc tgc aga aaa tac aat 268Asn Ser Cys Asp
Asn Cys Gln Pro Gly Thr Phe Cys Arg Lys Tyr Asn 30 35 40 cca gtc
tgc aag agc tgc cct cca agt acc ttc tcc agc ata ggt gga 316Pro Val
Cys Lys Ser Cys Pro Pro Ser Thr Phe Ser Ser Ile Gly Gly 45 50 55
cag ccg aac tgt aac atc tgc aga gtg tgt gca ggc tat ttc agg ttc
364Gln Pro Asn Cys Asn Ile Cys Arg Val Cys Ala Gly Tyr Phe Arg Phe
60 65 70 aag aag ttt tgc tcc tct acc cac aac gcg gag tgt gag tgc
att gaa 412Lys Lys Phe Cys Ser Ser Thr His Asn Ala Glu Cys Glu Cys
Ile Glu 75 80 85 gga ttc cat tgc ttg ggg cca cag tgc acc aga tgt
gaa aag gac tgc 460Gly Phe His Cys Leu Gly Pro Gln Cys Thr Arg Cys
Glu Lys Asp Cys 90 95 100 105 agg cct ggc cag gag cta acg aag cag
ggt tgc aaa acc tgt agc ttg 508Arg Pro Gly Gln Glu Leu Thr Lys Gln
Gly Cys Lys Thr Cys Ser Leu 110 115 120 gga aca ttt aat gac cag aac
ggt act ggc gtc tgt cga ccc tgg acg 556Gly Thr Phe Asn Asp Gln Asn
Gly Thr Gly Val Cys Arg Pro Trp Thr 125 130 135 aac tgc tct cta gac
gga agg tct gtg ctt aag acc ggg acc acg gag 604Asn Cys Ser Leu Asp
Gly Arg Ser Val Leu Lys Thr Gly Thr Thr Glu 140 145 150 aag gac gtg
gtg tgt gga ccc cct gtg gtg agc ttc tct ccc agt acc 652Lys Asp Val
Val Cys Gly Pro Pro Val Val Ser Phe Ser Pro Ser Thr 155 160 165 acc
att tct gtg act cca gag gga gga cca gga ggg cac tcc ttg cag 700Thr
Ile Ser Val Thr Pro Glu Gly Gly Pro Gly Gly His Ser Leu Gln 170 175
180 185 gtc ctt acc ttg ttc ctg gcg ctg aca tcg gct ttg ctg ctg gcc
ctg 748Val Leu Thr Leu Phe Leu Ala Leu Thr Ser Ala Leu Leu Leu Ala
Leu 190 195 200 atc ttc att act ctc ctg ttc tct gtg ctc aaa tgg atc
agg aaa aaa 796Ile Phe Ile Thr Leu Leu Phe Ser Val Leu Lys Trp Ile
Arg Lys Lys 205 210 215 ttc ccc cac ata ttc aag caa cca ttt aag aag
acc act gga gca gct 844Phe Pro His Ile Phe Lys Gln Pro Phe Lys Lys
Thr Thr Gly Ala Ala 220 225 230 caa gag gaa gat gct tgt agc tgc cga
tgt cca cag gaa gaa gaa gga 892Gln Glu Glu Asp Ala Cys Ser Cys Arg
Cys Pro Gln Glu Glu Glu Gly 235 240 245 gga gga gga ggc tat gag ctg
tga tgtactatcc taggagatgt gtgggccgaa 946Gly Gly Gly Gly Tyr Glu Leu
250 255 accgagaagc actaggaccc caccatcctg tggaacagca caagcaaccc
caccaccctg 1006ttcttacaca tcatcctaga tgatgtgtgg gcgcgcacct
catccaagtc tcttctaacg 1066ctaacatatt tgtctttacc ttttttaaat
ctttttttaa atttaaattt tatgtgtgtg 1126agtgttttgc ctgcctgtat
gcacacgtgt gtgtgtgtgt gtgtgtgaca ctcctgatgc 1186ctgaggaggt
cagaagagaa agggttggtt ccataagaac tggagttatg gatggctgtg
1246agccggnnng ataggtcggg acggagacct gtcttcttat tttaacgtga
ctgtataata 1306aaaaaaaaat gatatttcgg gaattgtaga gattctcctg
acacccttct agttaatgat 1366ctaagaggaa ttgttgatac gtagtatact
gtatatgtgt atgtatatgt atatgtatat 1426ataagactct tttactgtca
aagtcaacct agagtgtctg gttaccaggt caattttatt 1486ggacatttta
cgtcacacac acacacacac acacacacac acgtttatac tacgtactgt
1546tatcggtatt ctacgtcata taatgggata gggtaaaagg aaaccaaaga
gtgagtgata 1606ttattgtgga ggtgacagac taccccttct gggtacgtag
ggacagacct ccttcggact 1666gtctaaaact ccccttagaa gtctcgtcaa
gttcccggac gaagaggaca gaggagacac 1726agtccgaaaa gttatttttc
cggcaaatcc tttccctgtt tcgtgacact ccaccccttg 1786tggacacttg
agtgtcatcc ttgcgccgga aggtcaggtg gtacccgtct gtaggggcgg
1846ggagacagag ccgcggggga gctacgagaa tcgactcaca gggcgccccg
ggcttcgcaa 1906atgaaacttt tttaatctca caagtttcgt ccgggctcgg
cggacctatg gcgtcgatcc 1966ttattacctt atcctggcgc caagataaaa
caaccaaaag ccttgactcc ggtactaatt 2026ctccctgccg gcccccgtaa
gcataacgcg gcgatctcca ctttaagaac ctggccgcgt 2086tctgcctggt
ctcgctttcg taaacggttc ttacaaaagt aattagttct tgctttcagc
2146ctccaagctt ctgctagtct atggcagcat caaggctggt atttgctacg
gctgaccgct 2206acgccgccgc aataagggta ctgggcggcc cgtcgaaggc
cctttggttt cagaaaccca 2266aggcccccct cataccaacg tttcgacttt
gattcttgcc ggtacgtggt ggtgggtgcc 2326ttagctcttt ctcgatagtt agac
23504256PRTMus musculus 4Met Gly Asn Asn Cys Tyr Asn Val Val Val
Ile Val Leu Leu Leu Val 1 5 10 15 Gly Cys Glu Lys Val Gly Ala Val
Gln Asn Ser Cys Asp Asn Cys Gln 20 25 30 Pro Gly Thr Phe Cys Arg
Lys Tyr Asn Pro Val Cys Lys Ser Cys Pro 35 40 45 Pro Ser Thr Phe
Ser Ser Ile Gly Gly Gln Pro Asn Cys Asn Ile Cys 50 55 60 Arg Val
Cys Ala Gly Tyr Phe Arg Phe Lys Lys Phe Cys Ser Ser Thr 65 70 75 80
His Asn Ala Glu Cys Glu Cys Ile Glu Gly Phe His Cys Leu Gly Pro 85
90 95 Gln Cys Thr Arg Cys Glu Lys Asp Cys Arg Pro Gly Gln Glu Leu
Thr 100 105 110 Lys Gln Gly Cys Lys Thr Cys Ser Leu Gly Thr Phe Asn
Asp Gln Asn 115 120 125 Gly Thr Gly Val Cys Arg Pro Trp Thr Asn Cys
Ser Leu Asp Gly Arg 130 135 140 Ser Val Leu Lys Thr Gly Thr Thr Glu
Lys Asp Val Val Cys Gly Pro 145 150 155 160 Pro Val Val Ser Phe Ser
Pro Ser Thr Thr Ile Ser Val Thr Pro Glu 165 170 175 Gly Gly Pro Gly
Gly His Ser Leu Gln Val Leu Thr Leu Phe Leu Ala 180 185 190 Leu Thr
Ser Ala Leu Leu Leu Ala Leu Ile Phe Ile Thr Leu Leu Phe 195 200 205
Ser Val Leu Lys Trp Ile Arg Lys Lys Phe Pro His Ile Phe Lys Gln 210
215 220 Pro Phe Lys Lys Thr Thr Gly Ala Ala Gln Glu Glu Asp Ala Cys
Ser 225 230 235 240 Cys Arg Cys Pro Gln Glu Glu Glu Gly Gly Gly Gly
Gly Tyr Glu Leu 245 250 255 51459DNAArtificial SequenceAnti-CD19
BBzeta CAR 5atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca
cgccgccagg 60ccggacatcc agatgacaca gactacatcc tccctgtctg cctctctggg
agacagagtc 120accatcagtt gcagggcaag tcaggacatt agtaaatatt
taaattggta tcagcagaaa 180ccagatggaa ctgttaaact cctgatctac
catacatcaa gattacactc aggagtccca 240tcaaggttca gtggcagtgg
gtctggaaca gattattctc tcaccattag caacctggag 300caagaagata
ttgccactta cttttgccaa cagggtaata cgcttccgta cacgttcgga
360ggggggacca agctggagat cacaggtggc ggtggctcgg gcggtggtgg
gtcgggtggc 420ggcggatctg aggtgaaact gcaggagtca ggacctggcc
tggtggcgcc ctcacagagc 480ctgtccgtca catgcactgt ctcaggggtc
tcattacccg actatggtgt aagctggatt 540cgccagcctc cacgaaaggg
tctggagtgg ctgggagtaa tatggggtag tgaaaccaca 600tactataatt
cagctctcaa atccagactg accatcatca aggacaactc caagagccaa
660gttttcttaa aaatgaacag tctgcaaact gatgacacag ccatttacta
ctgtgccaaa 720cattattact acggtggtag ctatgctatg gactactggg
gccaaggaac ctcagtcacc 780gtctcctcaa ccacgacgcc agcgccgcga
ccaccaacac cggcgcccac catcgcgtcg 840cagcccctgt ccctgcgccc
agaggcgtgc cggccagcgg cggggggcgc agtgcacacg 900agggggctgg
acttcgcctg tgatatctac atctgggcgc ccttggccgg gacttgtggg
960gtccttctcc tgtcactggt tatcaccctt tactgcaaac ggggcagaaa
gaaactcctg 1020tatatattca aacaaccatt tatgagacca gtacaaacta
ctcaagagga agatggctgt 1080agctgccgat ttccagaaga agaagaagga
ggatgtgaac tgagagtgaa gttcagcagg 1140agcgcagacg cccccgcgta
ccagcagggc cagaaccagc tctataacga gctcaatcta 1200ggacgaagag
aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg
1260ggaaagccga gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca
gaaagataag 1320atggcggagg cctacagtga gattgggatg aaaggcgagc
gccggagggg caaggggcac 1380gatggccttt accagggtct cagtacagcc
accaaggaca cctacgacgc ccttcacatg 1440caggccctgc cccctcgct
14596486PRTArtificial SequenceAnti-CD19 BBzeta CAR 6Met Ala Leu Pro
Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1 5 10 15 His Ala
Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu 20 25 30
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35
40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly
Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser
Gly Val Pro65 70 75 80 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala
Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe
Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 130 135 140 Val Lys Leu
Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser145 150 155 160
Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly 165
170 175 Val Ser Trp Ile
Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly 180 185 190 Val Ile
Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser 195 200 205
Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys 210
215 220 Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
Lys225 230 235 240 His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr
Trp Gly Gln Gly 245 250 255 Thr Ser Val Thr Val Ser Ser Thr Thr Thr
Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr Ile Ala Ser
Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg Pro Ala Ala
Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe Ala Cys Asp
Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly305 310 315 320 Val
Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg 325 330
335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln
340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu
Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg
Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
Tyr Asn Glu Leu Asn Leu385 390 395 400 Gly Arg Arg Glu Glu Tyr Asp
Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu Met Gly Gly
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430 Tyr Asn Glu
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435 440 445 Gly
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 450 455
460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
Met465 470 475 480 Gln Ala Leu Pro Pro Arg 485 763DNAArtificial
SequenceCD8 leader 7atggccttac cagtgaccgc cttgctcctg ccgctggcct
tgctgctcca cgccgccagg 60ccg 63821PRTArtificial SequenceCD8 leader
8Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1 5
10 15 His Ala Ala Arg Pro 20 9726DNAArtificial SequenceAnti-CD19
scFv 9gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga
cagagtcacc 60atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca
gcagaaacca 120gatggaactg ttaaactcct gatctaccat acatcaagat
tacactcagg agtcccatca 180aggttcagtg gcagtgggtc tggaacagat
tattctctca ccattagcaa cctggagcaa 240gaagatattg ccacttactt
ttgccaacag ggtaatacgc ttccgtacac gttcggaggg 300gggaccaagc
tggagatcac aggtggcggt ggctcgggcg gtggtgggtc gggtggcggc
360ggatctgagg tgaaactgca ggagtcagga cctggcctgg tggcgccctc
acagagcctg 420tccgtcacat gcactgtctc aggggtctca ttacccgact
atggtgtaag ctggattcgc 480cagcctccac gaaagggtct ggagtggctg
ggagtaatat ggggtagtga aaccacatac 540tataattcag ctctcaaatc
cagactgacc atcatcaagg acaactccaa gagccaagtt 600ttcttaaaaa
tgaacagtct gcaaactgat gacacagcca tttactactg tgccaaacat
660tattactacg gtggtagcta tgctatggac tactggggcc aaggaacctc
agtcaccgtc 720tcctca 72610242PRTArtificial SequenceAnti-CD19 scFv
10Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly1
5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys
Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys
Leu Leu Ile 35 40 45 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu
Thr Ile Ser Asn Leu Glu Gln65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe
Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly Ser 100 105 110 Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu 115 120 125 Ser
Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys 130 135
140 Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile
Arg145 150 155 160 Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val
Ile Trp Gly Ser 165 170 175 Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys
Ser Arg Leu Thr Ile Ile 180 185 190 Lys Asp Asn Ser Lys Ser Gln Val
Phe Leu Lys Met Asn Ser Leu Gln 195 200 205 Thr Asp Asp Thr Ala Ile
Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly 210 215 220 Gly Ser Tyr Ala
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val225 230 235 240 Ser
Ser11135DNAArtificial SequenceCD8 Hinge 11accacgacgc cagcgccgcg
accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 60tccctgcgcc cagaggcgtg
ccggccagcg gcggggggcg cagtgcacac gagggggctg 120gacttcgcct gtgat
1351245PRTArtificial SequenceCD8 Hinge 12Thr Thr Thr Pro Ala Pro
Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala1 5 10 15 Ser Gln Pro Leu
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 20 25 30 Gly Ala
Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 35 40 45
1372DNAArtificial SequenceCD8 Transmembrane Domain 13atctacatct
gggcgccctt ggccgggact tgtggggtcc ttctcctgtc actggttatc 60accctttact
gc 721424PRTArtificial SequenceCD8 Transmembrane Domain 14Ile Tyr
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu1 5 10 15
Ser Leu Val Ile Thr Leu Tyr Cys 20 15126DNAArtificial Sequence4-1BB
signaling domain 15aaacggggca gaaagaaact cctgtatata ttcaaacaac
catttatgag accagtacaa 60actactcaag aggaagatgg ctgtagctgc cgatttccag
aagaagaaga aggaggatgt 120gaactg 1261642PRTArtificial Sequence4-1BB
signaling domain 16Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys
Gln Pro Phe Met1 5 10 15 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp
Gly Cys Ser Cys Arg Phe 20 25 30 Pro Glu Glu Glu Glu Gly Gly Cys
Glu Leu 35 40 17336DNAArtificial SequenceCD3zeta signaling domain
17agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc
60tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc
120cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg
cctgtacaat 180gaactgcaga aagataagat ggcggaggcc tacagtgaga
ttgggatgaa aggcgagcgc 240cggaggggca aggggcacga tggcctttac
cagggtctca gtacagccac caaggacacc 300tacgacgccc ttcacatgca
ggccctgccc cctcgc 33618112PRTArtificial SequenceCD3zeta signaling
domain 18Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
Gln Gly1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp
Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu
Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg65 70 75 80 Arg Arg Gly Lys
Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110
191459DNAArtificial SequenceAnti-CD19 BBzeta CAR 19atggccttac
cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60ccggacatcc
agatgacaca gactacatcc tccctgtctg cctctctggg agacagagtc
120accatcagtt gcagggcaag tcaggacatt agtaaatatt taaattggta
tcagcagaaa 180ccagatggaa ctgttaaact cctgatctac catacatcaa
gattacactc aggagtccca 240tcaaggttca gtggcagtgg gtctggaaca
gattattctc tcaccattag caacctggag 300caagaagata ttgccactta
cttttgccaa cagggtaata cgcttccgta cacgttcgga 360ggggggacca
agctggagat cacaggtggc ggtggctcgg gcggtggtgg gtcgggtggc
420ggcggatctg aggtgaaact gcaggagtca ggacctggcc tggtggcgcc
ctcacagagc 480ctgtccgtca catgcactgt ctcaggggtc tcattacccg
actatggtgt aagctggatt 540cgccagcctc cacgaaaggg tctggagtgg
ctgggagtaa tatggggtag tgaaaccaca 600tactataatt cagctctcaa
atccagactg accatcatca aggacaactc caagagccaa 660gttttcttaa
aaatgaacag tctgcaaact gatgacacag ccatttacta ctgtgccaaa
720cattattact acggtggtag ctatgctatg gactactggg gccaaggaac
ctcagtcacc 780gtctcctcaa ccacgacgcc agcgccgcga ccaccaacac
cggcgcccac catcgcgtcg 840cagcccctgt ccctgcgccc agaggcgtgc
cggccagcgg cggggggcgc agtgcacacg 900agggggctgg acttcgcctg
tgatatctac atctgggcgc ccttggccgg gacttgtggg 960gtccttctcc
tgtcactggt tatcaccctt tactgcaaac ggggcagaaa gaaactcctg
1020tatatattca aacaaccatt tatgagacca gtacaaacta ctcaagagga
agatggctgt 1080agctgccgat ttccagaaga agaagaagga ggatgtgaac
tgagagtgaa gttcagcagg 1140agcgcagacg cccccgcgta caagcagggc
cagaaccagc tctataacga gctcaatcta 1200ggacgaagag aggagtacga
tgttttggac aagagacgtg gccgggaccc tgagatgggg 1260ggaaagccga
gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag
1320atggcggagg cctacagtga gattgggatg aaaggcgagc gccggagggg
caaggggcac 1380gatggccttt accagggtct cagtacagcc accaaggaca
cctacgacgc ccttcacatg 1440caggccctgc cccctcgct
145920486PRTArtificial SequenceAnti-CD19 BBzeta CAR 20Met Ala Leu
Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1 5 10 15 His
Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu 20 25
30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln
35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp
Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His
Ser Gly Val Pro65 70 75 80 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln Glu Asp Ile
Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu Pro Tyr Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 130 135 140 Val Lys
Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser145 150 155
160 Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly
165 170 175 Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp
Leu Gly 180 185 190 Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser
Ala Leu Lys Ser 195 200 205 Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys
Ser Gln Val Phe Leu Lys 210 215 220 Met Asn Ser Leu Gln Thr Asp Asp
Thr Ala Ile Tyr Tyr Cys Ala Lys225 230 235 240 His Tyr Tyr Tyr Gly
Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 245 250 255 Thr Ser Val
Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr
Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280
285 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
290 295 300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr
Cys Gly305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
Cys Lys Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln
Pro Phe Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly
Cys Ser Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu
Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr
Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu385 390 395 400
Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405
410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp
Thr Tyr Asp Ala Leu His Met465 470 475 480 Gln Ala Leu Pro Pro Arg
485 21336DNAArtificial SequenceCD3zeta signaling domain
21agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc
60tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc
120cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg
cctgtacaat 180gaactgcaga aagataagat ggcggaggcc tacagtgaga
ttgggatgaa aggcgagcgc 240cggaggggca aggggcacga tggcctttac
cagggtctca gtacagccac caaggacacc 300tacgacgccc ttcacatgca
ggccctgccc cctcgc 33622112PRTArtificial SequenceCD3zeta signaling
domain 22Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys
Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp
Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu
Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys
Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105
110
* * * * *